As filed with the Securities and Exchange Commission on May 2, 2003
Registration No. 333-102969
================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------
AMENDMENT NO. 3
TO
FORM S-2
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
----------
REVLON, INC.
(Exact Name of Registrant as Specified in Its Charter)
DELAWARE 13-3662955
(State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification Number)
625 MADISON AVENUE
NEW YORK, NY 10022
(212) 527-4000
(Address, Including Zip Code, and Telephone Number, Including Area Code, of
registrant's principal executive offices)
ROBERT K. KRETZMAN, ESQ.
REVLON, INC.
625 MADISON AVENUE
NEW YORK, NY 10022
(212) 527-4000
(Name, Address, Including Zip Code, and Telephone Number, Including Area
Code, of Agent For Service)
----------
COPY TO:
STACY J. KANTER, ESQ.
SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP
FOUR TIMES SQUARE
NEW YORK, NEW YORK 10036
(212) 735-3000
FAX: (212) 735-2000
APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE TO THE PUBLIC: As soon
as practicable after the effective date of this Registration Statement.
If any of the securities being registered on this Form are to be offered
on a delayed or continuous basis pursuant to Rule 415 under the Securities Act
of 1933, other than securities offered only in connection with dividend or
interest reinvestment plans, check the following box. [X]
If the registrant elects to deliver its latest annual report to security
holders, or a complete and legible facsimile thereof, pursuant to Item 11(a)(1)
of this form, check the following box. [ ]
If this form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, please check the following
box and list the Securities Act registration statement number of the earlier
effective registration statement for the same offering. [ ]
If this form is a post-effective amendment filed pursuant to Rule 462(c)
under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering. [ ]
If delivery of the prospectus is expected to be made pursuant to Rule 434,
please check the following box. [ ]
----------
THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR
DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT
SHALL FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION
STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(a) OF
THE SECURITIES ACT OF 1933 OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME
EFFECTIVE ON SUCH DATE AS THE COMMISSION, ACTING PURSUANT TO SAID SECTION 8(a),
MAY DETERMINE.
================================================================================
EXPLANATORY NOTE
The subscription price for our shares of Class A common stock referred to in
this Registration Statement shall be equal to eighty percent (80%) of the
greater of the closing price per share of our Class A common stock on the New
York Stock Exchange on (i) the trading day before the date that our board of
directors approved this rights offering, which was $2.88 per share, and (ii)
the record date of this rights offering. Except where otherwise stated,
references in this Registration Statement to numbers of shares of our Class A
common stock to be issued in this rights offering and to the proportionate
ownership and voting power by MacAndrews & Forbes Holdings Inc. of our stock
after this rights offering assume a subscription price of $2.30 per share
(which represents 80% of the closing price per share of our Class A common
stock on the New York Stock Exchange on the trading day before the date that
our board of directors approved the rights offering, which was $2.88 per
share).
[sidebar start]
The information in this prospectus is not complete and may be changed. We may
not sell these securities until the registration statement filed with the
Securities and Exchange Commission is effective. This prospectus is not an
offer to sell these securities and it is not soliciting an offer to buy these
securities in any state where the offer or sale is not permitted.
[sidebar end]
Subject to Completion, dated May 2, 2003.
PROSPECTUS
3,717,391 Shares
REVLON, INC.
CLASS A COMMON STOCK
----------------
We are distributing at no charge to the holders of our Class A and Class B
common stock transferable subscription rights to purchase up to an aggregate of
21,739,130 shares of our Class A common stock at a cash subscription price of
$ per share. This rights offering is comprised of an offering of subscription
rights to purchase up to 3,717,391 shares of our Class A common stock to all
holders of our Class A and Class B common stock, other than MacAndrews &
Forbes, one of our affiliates, and the distribution to MacAndrews & Forbes of
subscription rights to purchase up to 18,021,739 shares of our Class A common
stock. However, MacAndrews & Forbes has agreed not to exercise or sell the
subscription rights that it receives and has indicated that it does not intend
to purchase any subscription rights on the open market. Instead, MacAndrews &
Forbes has agreed to purchase the shares of our Class A Common Stock that it
would otherwise have been entitled to receive pursuant to its basic
subscription privilege in a private placement direct from us, under an
investment agreement described in this prospectus. This rights offering is
being made to help fund a portion of the costs and expenses of the
stabilization and growth phase of our plan discussed in this prospectus.
The total purchase price of shares offered in this rights offering and the
offering of shares to MacAndrews & Forbes described above will be approximately
$50,000,000. You will not be entitled to receive any subscription rights unless
you are a stockholder of record as of the close of business on , 2003.
The subscription rights will expire if they are not exercised by 5:00
p.m., New York City time, on , 2003, the expected expiration date of this
rights offering. We, in our sole discretion, may extend the period for
exercising the subscription rights. We will extend the duration of the rights
offering as required by applicable law, and may choose to extend it if we
decide that changes in the market price of our Class A common stock warrant an
extension or if we decide to give investors more time to exercise their
subscription rights in this rights offering. However, because MacAndrews &
Forbes has agreed to back-stop this rights offering, we will not need to extend
the exercise period because the back-stop arrangement ensures that we will
receive total gross proceeds of $50 million. Subscription rights that are not
exercised by the expiration date of this rights offering will expire and will
have no value. You should carefully consider whether or not to exercise or sell
your subscription rights before the expiration date.
Shares of our Class A common stock are quoted on the New York Stock
Exchange under the symbol "REV." The last sale price of our Class A common
stock on May 1, 2003 was $3.15 per share. We anticipate that the subscription
rights will be traded on the New York Stock Exchange under the symbol "REV RT."
PER SHARE AGGREGATE
----------- --------------------
Subscription Price .............. $ $ 50,000,000(1)
Estimated Expenses .............. $ $ 2,625,828
Net Proceeds to Revlon .......... $ $ 47,374,172
----------------
(1) Includes proceeds from the purchase of shares by MacAndrews &
Forbes under the Investment Agreement, including under the
back-stop arrangement described elsewhere in this prospectus.
AN INVESTMENT IN OUR CLASS A COMMON STOCK INVOLVES RISKS. YOU SHOULD
CONSIDER CAREFULLY THE RISK FACTORS BEGINNING ON PAGE 14 IN THIS PROSPECTUS
BEFORE EXERCISING OR SELLING YOUR SUBSCRIPTION RIGHTS.
Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or determined if
this prospectus is truthful or complete. Any representation to the contrary is
a criminal offense. The securities are not being offered in any jurisdiction
where the offer is not permitted.
----------------
The date of this prospectus is , 2003
TABLE OF CONTENTS
PAGE
-----
Prospectus Summary ....................................... 1
Questions and Answers About the Rights Offering .......... 8
Risk Factors ............................................. 14
Forward-Looking Statements ............................... 24
Unaudited Pro Forma Consolidated Financial Data .......... 27
The Rights Offering ...................................... 29
Investment Agreement ..................................... 43
Description of Capital Stock ............................. 44
Use of Proceeds .......................................... 47
Dilution ................................................. 48
Capitalization ........................................... 49
United States Federal Income Tax Consequences ............ 50
Legal Matters ............................................ 51
Experts .................................................. 51
Incorporation of Certain Documents by Reference .......... 51
Where You Can Find More Information ...................... 52
----------------
i
PROSPECTUS SUMMARY
The following summary highlights selected information from this prospectus
and may not contain all of the information that is important to you. This
prospectus includes specific terms of this rights offering, as well as
information regarding our business. We encourage you to read this prospectus in
its entirety. You should pay special attention to the "Risk Factors" section of
this prospectus. All references to "we," "our," "ours," and "us," or "Revlon"
in this prospectus are to Revlon, Inc. and its subsidiaries, unless otherwise
indicated. However, in the descriptions of the subscription rights and related
matters, these terms refer solely to Revlon, Inc. and not to any of our
subsidiaries. All U.S. market share and market position data herein for our
brands are based upon retail dollar sales, which are derived from ACNielsen
data. ACNielsen measures retail sales volume of products sold in the U.S.
mass-market distribution channel. Such data represent ACNielsen's estimates
based upon data gathered by ACNielsen from market samples and are therefore
subject to some degree of variance. Additionally, as of August 4, 2001,
ACNielsen's data does not reflect sales volume from Wal-Mart, Inc.
OUR COMPANY
We manufacture, market and sell an extensive array of cosmetics and skin
care, fragrances and personal care products. Revlon is one of the world's
best-known names in cosmetics and is a leading mass-market cosmetics brand. We
believe that our global brand name recognition, product quality and marketing
experience have enabled us to create one of the strongest consumer brand
franchises in the world. Our products are sold worldwide and are marketed under
such well-known brand names as Revlon, Colorstay, Revlon Age Defying,
Skinlights and Ultima II, as well as Almay in cosmetics; Almay Kinetin, Vitamin
C Absolutes, Eterna 27, Ultima II, and Jeanne Gatineau in skin care; Charlie in
fragrances; and High Dimension, Flex, Mitchum, Colorsilk, Jean Nate and Bozzano
in personal care products.
Revlon was founded by Charles Revson, who revolutionized the cosmetics
industry by introducing nail enamels matched to lipsticks in fashion colors
over 70 years ago. Today, we have leading market positions in a number of our
principal product categories in the U.S. mass-market distribution channel,
including the lip, face makeup and nail enamel categories. We also have leading
market positions in several product categories in certain markets outside of
the U.S., including in Australia, Canada, Mexico and South Africa. Our products
are sold in more than 100 countries across five continents.
The Company's Plan
Our plan consists of three main components: (1) the cost rationalization
phase; (2) the stabilization and growth phase; and (3) the accelerated growth
phase.
Phase 1 -- Cost Rationalization
In 1999 and 2000, we faced a number of strategic challenges. Accordingly,
through 2001 we focused our plan on lowering costs and improving operating
efficiency.
During 2001, we implemented several key elements of this phase of our
plan. For example, we:
o reduced departmental general and administrative expenses in our
operations;
o reduced manufacturing and warehousing square footage by approximately
55% during the period from November 2000 to December 31, 2001;
o closed our in-house advertising division and consolidated all
advertising for our Revlon and Almay brands with two prominent
advertising agencies (and further consolidated into a single agency in
2002); and
o implemented revised trade terms with our U.S. customers intended to
increase sell-through of our products, reduce merchandise returns and
claims for damages and drive market growth.
1
We believe that our actions during 2000 and 2001 lowered our cost
structure overall and improved our manufacturing and operating efficiency,
creating a platform for the stabilization and growth stage of our plan.
Phase 2 -- Stabilization and Growth
In February 2002, we announced the appointment of Jack L. Stahl, former
president and chief operating officer of The Coca-Cola Company, as our new
President and Chief Executive Officer.
Following the appointment of Mr. Stahl, we undertook an extensive review
and evaluation of our business to establish specific integrated objectives and
actions to advance the next stage in our plan. As a result of this review, we
established three principal objectives:
o creating and developing the most consumer-preferred brands;
o becoming the most valuable partner to our retailers; and
o becoming a top company where people choose to work.
We also conducted detailed evaluations and research of the strengths of
the Revlon brand (and we are continuing to conduct similar evalutions and
research for our other major brands); our advertising and promotional efforts;
our relationships with our retailers and consumers; our retail in-store
presence; and the strength and skills of our organization. As a result, we
developed the following key actions and investments to support the
stabilization and growth phase of our plan:
o Increase advertising and media spending and effectiveness. We expect to
increase our media spending and advertising support. We will also seek
to improve the effectiveness of our marketing, including our
advertising, by, among other things, ensuring consistent messaging and
imagery in our advertising, in the graphics included in our wall
displays and in our other marketing materials.
o Increase the marketing effectiveness of our wall displays. Beginning in
the first quarter of 2003, we intend to make significant improvements to
our retail wall displays by streamlining our product assortment and
reconfiguring product placement, which we believe will optimize
cross-selling among our various product categories on the wall displays
and make the displays easier to merchandise and stock. We also intend to
continue to roll out our new wall displays, which we began in 2002. In
addition, we intend to enhance merchandiser coverage to improve in-store
stock levels and continue to develop our tamper evident program to
reduce damages. We also intend to work with our retail customers to
improve replenishment of our products on the wall displays and to
minimize out-of-stocks at our customers.
o Adopt revised pricing strategies. We believe that we can increase sales
by selectively adjusting prices on certain stock keeping units, or SKUs,
to better align our pricing with product benefits and competitive
benchmarks.
o Further strengthen our new product development process. We are
developing a cross-functional new product development process intended
to optimize our ability to bring to market our new product offerings to
ensure that we have products in key trend categories.
o Implement a comprehensive program to develop and train our employees. We
are implementing a comprehensive program to further develop the
management, leadership and communication skills of our employees, which
we will regularly assess as part of our goal to become a top company
where people choose to work.
In December 2002, we announced that we would accelerate the implementation
of the stabilization and growth phase of our plan. We recorded charges of
approximately $100 million in the fourth quarter of 2002 and currently expect
to record additional charges not to exceed $60 million during 2003 and 2004.
These charges relate to various aspects of the stabilization and growth phase
of our plan, primarily stemming from sales returns and inventory writedowns
from a selective reduction
2
of SKUs, reduced distribution of the Ultima II brand, allowances stemming from
selective price adjustments on certain products, professional expenses
associated with the development of, and research in relation to, and execution
of the stabilization and growth phase of our plan and writedowns associated
with reconfiguring existing wall displays at our retail customers. These
charges exclude brand support expenses and training and development costs.
Phase 3 -- Accelerated Growth
We intend to capitalize on the actions taken during the stabilization and
growth phase of our plan, with the objective of increasing revenues and
profitability over the long term.
RECENT DEVELOPMENTS
MacAndrews & Forbes Investments
In December 2002, our principal stockholder, MacAndrews & Forbes Holdings
Inc. ("MacAndrews Holdings"), a corporation wholly owned through Mafco Holdings
Inc. ("Mafco Holdings" and, together with MacAndrews Holdings, "MacAndrews &
Forbes"), by Ronald O. Perelman, proposed providing us with up to $150 million
in cash in order to help fund a portion of the costs and expenses associated
with implementing the stabilization and growth phase of our plan and for
general corporate purposes. Our board of directors appointed a special
committee of independent directors to evaluate the proposal made by MacAndrews
& Forbes. The special committee reviewed and considered the proposal and
negotiated enhancements to the terms of the proposal. In February 2003, the
enhanced proposal was recommended to our board of directors by the special
committee and approved by our full board.
This rights offering is part of the enhanced proposal. As a holder of our
common stock, MacAndrews & Forbes will receive its pro rata subscription rights
in this rights offering and would also be entitled to exercise an
over-subscription privilege. However, MacAndrews & Forbes has agreed not to
exercise either its basic or its over-subscription privilege. Instead,
MacAndrews & Forbes has agreed to purchase the shares of our Class A common
stock that it would otherwise have been entitled to acquire pursuant to its
basic subscription privilege (equal to approximately 83% of the the shares
available for purchase under the subscription rights distributed in this rights
offering, or approximately $41.5 million) in a private placement direct from
us. In addition, if any shares remain following the exercise of basic
subscription privileges and over-subscription privileges by other rights
holders, MacAndrews & Forbes will back-stop this rights offering by purchasing
the remaining shares of Class A common stock offered but not purchased by other
rights holders (up to approximately 17% of the shares offered in this rights
offering, or an additional approximate $8.5 million), also in a private
placement.
In accordance with the enhanced proposal, MacAndrews & Forbes has also
provided a $100 million term loan to our subsidiary, Revlon Consumer Products
Corporation, referred to herein as "Products Corporation." If, prior to the
consummation of this rights offering, Products Corporation has fully drawn the
MacAndrews & Forbes $100 million term loan and the implementation of the
stabilization and growth phase of our plan causes us to require some or all of
the $50 million of funds that we would raise from this rights offering,
MacAndrews & Forbes has agreed to advance us these funds prior to the closing
of this rights offering by purchasing up to $50 million of newly-issued shares
of our Series C preferred stock, which would be redeemed with the proceeds we
receive from this rights offering (this investment in our Series C preferred
stock is referred to in this prospectus as the "$50 million Series C preferred
stock investment"). The MacAndrews & Forbes $100 million term loan has a final
maturity date of December 1, 2005 and interest on such loan of 12.0% is not
payable in cash, but will accrue and be added to the principal amount each
quarter and be paid in full at final maturity. We expect that we will issue the
subscription rights and consummate this rights offering in the second quarter
of 2003. Based on this expectation, we anticipate that we will draw on the
MacAndrews & Forbes $100 million term loan before this rights offering is
consummated in order to
3
continue the implementation of the stabilization and growth phase of our plan
and for general corporate purposes. However, we do not currently anticipate
that we will require that MacAndrews & Forbes make the $50 million Series C
preferred stock investment.
Additionally, MacAndrews & Forbes has also agreed to provide Products
Corporation with an additional $40 million line of credit during 2003, which
amount will increase to $65 million on January 1, 2004, which we refer to as
the "$40-65 million line of credit", and which will be available to Products
Corporation through December 31, 2004, provided that the MacAndrews & Forbes
$100 million term loan is fully drawn and MacAndrews & Forbes has purchased an
aggregate of $50 million of our Series C preferred stock (or if we have
consummated this rights offering and redeemed any outstanding shares of Series
C preferred stock). The $40-65 million line of credit will be available through
December 31, 2004 and will bear interest payable in cash at a rate of the
lesser of (i) 12.0% and (ii) 0.25% less than the rate payable from time to time
on Eurodollar loans under Products Corporation's existing credit agreement
(which rate, after giving effect to the amendment to Products Corporation's
existing credit agreement discussed below, is 8.25%, as of March 1, 2003). We
do not currently expect that we will draw on the $40-65 million line of credit
during 2003.
In connection with the transactions with MacAndrews & Forbes described
above, and as a result of our operating results for the fourth quarter of 2002
and the effect of the acceleration of the implementation of the stabilization
and growth phase of our plan, we entered into an amendment in February 2003 of
our existing credit agreement with our bank lenders and secured waivers of
compliance with certain covenants under our existing credit agreement. In
particular, EBITDA (as defined in our existing credit agreement) was $35.2
million for the four consecutive fiscal quarters ended December 31, 2002, which
was less than the minimum of $210 million required under the EBITDA covenant of
our credit agreement for that period, and our leverage ratio was 5.09:1.00,
which was in excess of the maximum ratio of 1.4:1.00 permitted under the
leverage ratio covenant of our credit agreement for that period. Accordingly,
we sought and secured waivers of compliance with these covenants for the fourth
quarter of 2002 and, in light of our expectation that the continued
implementation of the stabilization and growth phase of our plan would affect
our ability to comply with these covenants during 2003, we also secured an
amendment to eliminate the EBITDA and leverage ratio covenants for the first
three quarters of 2003 and a waiver of compliance with such covenants for the
four quarters ending December 31, 2003 expiring on January 31, 2004.
The amendment to our existing credit agreement also included the
substitution of a minimum liquidity covenant requiring us to maintain a minimum
of $20 million in liquidity from all available sources at all times through
January 31, 2004 and certain other amendments to allow for the MacAndrews &
Forbes $100 million term loan, the $40-65 million line of credit, this rights
offering, and the implementation of the stabilization and growth phase of our
plan, including specific exceptions from the limitations under the indebtedness
covenant to permit such investments and to exclude the proceeds from such
investments from the mandatory prepayment provisions of the credit agreement,
and to increase the maximum limit on capital expenditures from $100 million to
$115 million for 2003. The amendment also increased the applicable margin on
loans under the existing credit agreement by 0.5%, the incremental cost of
which to us, assuming the credit agreement is fully drawn, would be $1.1
million from February 5, 2003 through the end of 2003.
First Quarter Results
On April 24, 2003, we announced our results for the fiscal quarter ended
March 31, 2003. Our net sales in the first quarter of 2003 increased 6% to $292
million, compared with net sales of $275 million in the same period in 2002.
The increase in sales was driven by growth for both our North American and
international operations, despite provisions for higher returns and allowances
associated with implementing the stabilization and growth phase of our plan. In
North America, net sales in the first quarter of 2003 grew 4% to $205 million,
compared to $196 million in the first quarter of 2002, primarily driven by
strong growth in color cosmetics and, to a lesser extent, hair color, partially
offset by lower sales from implements and anti-perspirants/deodorants. In our
international operations, net
4
sales in the first quarter of 2003 grew 10%, reflecting growth in the U.K.,
South Africa and certain markets in the Far East, as well as the benefit of
favorable foreign currency translation, partially offset by softness in Brazil
and Mexico.
Our operating loss in the first quarter of 2003 was $4.2 million, compared
to an operating loss of $4.3 million in the first quarter of 2002. This
performance primarily reflected the benefit of the sales growth, the absence of
executive severance in the first quarter of 2003, and significantly lower
restructuring expenses. These factors were almost entirely offset by higher
brand support, for both our North American and international operations, as well
as charges in the first quarter of 2003 of approximately $11 million associated
with implementing the stabilization and growth phase of our plan (excluding
brand support expenses or any training and development costs) and higher
general and administrative expenses. Our operating loss in the first quarter of
2003 included $0.5 million of restructuring expenses and $0.2 million of
additional consolidation costs, while our operating loss in the first quarter
of 2002 included expenses totaling $11.3 million, reflecting $6.5 million of
executive severance, $4.0 million of restructuring expenses, and $0.8 million
of additional consolidation costs. Net loss in the first quarter of 2003 was
$48.7 million, or $0.93 per diluted share, compared with a net loss of $46.1
million, or $0.88 per diluted share, in the first quarter of 2002. Cash flow
used for operating activities in the first quarter of 2003 was $60.5 million,
compared with cash flow used for operating activities of $41.7 million in the
first quarter of 2002.
The following tables set forth our unaudited consolidated results of
operations for the three months ended March 31, 2003 and March 31, 2002 and
certain balance sheet data as of March 31, 2003 and December 31, 2002.
THREE MONTHS ENDED
MARCH 31,
-----------------------------
(UNAUDITED)
2003 2002
-------------- --------------
(DOLLARS IN MILLIONS, EXCEPT
PER SHARE DATA)
STATEMENT OF OPERATIONS DATA:
Net sales ............................................ $ 292.0 $ 275.4
Cost of sales ........................................ 111.5 109.0
----------- -----------
Gross profit ........................................ 180.5 166.4
Selling, general and administrative expenses ......... 184.2 166.7
Restructuring costs .................................. 0.5 4.0
----------- -----------
Operating loss ...................................... (4.2) (4.3)
----------- -----------
Other expense (income):
Interest expense .................................... 41.4 39.2
Interest income ..................................... (0.5) (0.5)
Amortization of debt issuance costs ................. 2.0 1.9
Foreign currency losses (gains), net ................ 0.3 (0.6)
Miscellaneous, net .................................. 0.4 1.7
----------- -----------
Other expenses, net ............................... 43.6 41.7
----------- -----------
Loss before income taxes ............................. (47.8) (46.0)
Provision for income taxes ........................... 0.9 0.1
----------- -----------
Net loss ............................................. $ (48.7) $ (46.1)
=========== ===========
Basic and diluted net loss per common share .......... $ (0.93) $ (0.88)
=========== ===========
Weighted average number of common shares outstanding:
Basic and diluted ................................... 52,199,468 52,199,468
=========== ===========
5
MARCH 31, 2003 DECEMBER 31, 2002
---------------- ------------------
(UNAUDITED)
(DOLLARS IN MILLIONS)
BALANCE SHEET DATA:
ASSETS
Current assets:
Cash and cash equivalents ................................ $ 34.8 $ 85.8
Trade receivables, net ................................... 200.5 212.3
Inventories .............................................. 151.6 128.1
Prepaid expenses and other ............................... 51.1 39.6
---------- ----------
Total current assets ................................... 438.0 465.8
Property, plant and equipment, net ........................ 130.4 133.4
Other assets .............................................. 163.4 154.4
Goodwill, net ............................................. 185.9 185.9
---------- ----------
Total assets ........................................... $ 917.7 $ 939.5
========== ==========
LIABILITIES AND STOCKHOLDERS' DEFICIENCY
Current liabilities:
Short-term borrowings--third parties ..................... $ 26.9 $ 25.0
Accounts payable ......................................... 113.3 92.9
Accrued expenses and other ............................... 382.0 392.3
---------- ----------
Total current liabilities .............................. 522.2 510.2
Long-term debt ............................................ 1,764.6 1,750.1
Other long-term liabilities ............................... 318.6 320.0
Total stockholders' deficiency ............................ (1,687.7) (1,640.8)
---------- ----------
Total liabilities and stockholders' deficiency ......... $ 917.7 $ 939.5
========== ==========
--------
Our principal executive offices are located at 625 Madison Avenue, New
York, New York 10022. Our telephone number at that address is (212) 527-4000.
6
ORGANIZATION
The following sets forth a summary organizational chart for Revlon:
-------------------------
Mafco Holdings Inc.
-------------------------
100%
-------------------------
MacAndrews & Forbes
Holdings Inc.*
-------------------------
100%
-------------------------
REV Holdings LLC
("REV Holdings")
-------------------------
83%**
-------------------------
REVLON, INC.
-------------------------
100%
-------------------------
Revlon Consumer
Products Corporation
-------------------------
-------------------------
Operating Subsidiaries of
Revlon Consumer
Products Corporation
-------------------------
* MacAndrews & Forbes Holdings Inc. is wholly owned through Mafco
Holdings Inc. by Ronald O. Perelman.
** REV Holdings currently beneficially owns 11,650,000 shares of the
Class A common stock, par value $.01 per share, of Revlon, Inc.
(representing approximately 57% of the outstanding shares of Class A
common stock of Revlon, Inc.) and all of the outstanding 31,250,000
shares of Class B common stock, par value $.01 per share (each of
which is entitled to 10 votes), of Revlon, Inc., which together
represent approximately 83% of the outstanding shares of common stock
of Revlon, Inc. REV Holdings also currently beneficially owns all of
the outstanding 4,333 shares of Series B Convertible Preferred Stock,
par value $.01 per share, of Revlon, Inc. (each of which is entitled
to 100 votes and each of which is convertible into 100 shares of Class
A common stock), which, together with the Class A and Class B common
stock, represents approximately 97% of the combined voting power of
the outstanding shares of common and preferred stock of Revlon, Inc.
7
QUESTIONS AND ANSWERS ABOUT THE RIGHTS OFFERING
Q: What is this rights offering?
A: This rights offering is a distribution, at no charge, to holders of our
Class A and Class B common stock of one transferable subscription right to
purchase one additional share of our Class A common stock for each
shares of Class A or Class B common stock owned as of __________, 2003 (or
the "rights offering record date"), for a total of approximately
subscription rights. The maximum gross proceeds of this rights offering
will be $50,000,000, including at least $ from MacAndrews & Forbes in
relation to the purchase of 18,021,739 shares pursuant to a private
placement (excluding any proceeds received from it pursuant to the
back-stop).
Q: What is a subscription right?
A: Each full subscription right is a right to purchase one share of our Class
A common stock and carries with it a basic subscription privilege and an
over-subscription privilege.
Q: How many shares may I purchase if I exercise my subscription rights?
A: You will receive one transferable subscription right for each ___ shares of
Class A and Class B common stock that you owned on __________, 2003, the
rights offering record date. Each subscription right contains the basic
subscription privilege and the over-subscription privilege.
Q: What is the basic subscription privilege?
A: The basic subscription privilege of each subscription right entitles you to
purchase one share of our Class A common stock at the subscription price
of $_______ per share.
Q: What is the over-subscription privilege?
A: The over-subscription privilege of each subscription right entitles you, if
you fully exercise your basic subscription privilege, to subscribe for
additional shares of our Class A common stock at the same subscription
price per share on a pro rata basis if any shares are not purchased by
other holders of subscription rights (except MacAndrews & Forbes) under
their basic subscription privileges as of the expiration date. "Pro rata"
means in proportion to the number of shares of our Class A common stock
that you and the other subscription rights holders have purchased by
exercising your basic subscription privileges on your common stock
holdings. Although MacAndrews & Forbes, as a holder of Class A and Class B
common stock, would otherwise be entitled to this over-subscription
privilege, to enhance your over-subscription privileges, it has agreed to
waive this right to enhance the over-subscription privilege of our other
stockholders.
Q: What if there are an insufficient number of shares to satisfy the
over-subscription requests?
A: If there are an insufficient number of shares of our Class A common stock
available to fully satisfy the over-subscription requests of rights
holders, subscription rights holders who exercised their over-subscription
privilege will receive the available shares pro rata based on the number
of shares each subscription rights holder subscribed for under the basic
subscription privilege. Any excess subscription payments will be returned,
without interest or deduction, promptly after the expiration of this
rights offering.
Q: Why are you engaging in this rights offering?
A: This rights offering is being made to help fund a portion of the costs and
expenses of the stabilization and growth phase of our plan. MacAndrews &
Forbes has proposed to provide us up to $150 million to help fund a
portion of the costs and expenses associated with implementing the
stabilization and growth phase of our plan and for general corporate
purposes in the form of various investments, including the purchase of our
Class A common stock in connection with this rights offering. See
"--Recent Developments."
8
The proceeds from these various investments will be used to fund the
implementation of the stabilization and growth phase of our plan, which
involves increasing advertising and media spending, increasing the
marketing effectiveness of our wall displays, including by streamlining
the number of our SKUs, selectively adjusting prices on certain of our
products, optimizing product availability to consumers and further
strengthening our new product development process.
Q: What happens if I choose not to exercise my subscription rights?
A: You will retain your current number of shares of Class A common stock even
if you do not exercise your subscription rights. However, if you do not
exercise your subscription privileges, the percentage of our Class A
common stock that you own will decrease, and your voting and other rights
will be diluted to the extent that other stockholders exercise their basic
and over-subscription rights.
Q: Can your board of directors cancel this rights offering?
A: Yes. Our board of directors may decide to cancel this rights offering at
any time prior to the expiration of the rights offering and for any
reason. If we cancel this rights offering, any money received from
subscribing stockholders will be refunded promptly, without interest or
deduction.
Q: When will this rights offering expire?
A: The subscription rights will expire, if not exercised, at 5:00 p.m., New
York City time, on , 2003, unless we decide to extend this rights
offering until some later time. See "The Rights Offering--Expiration of
the Rights Offering and Extensions and Termination." The subscription
agent must actually receive all required documents and payments before
that time and date. There is no maximum duration for this rights offering.
Q: How do I exercise my subscription rights?
A: You may exercise your subscription rights by properly completing and
signing your subscription rights certificate. Your subscription rights
certificate, together with full payment of the subscription price, must be
received by the subscription agent on or prior to the expiration date of
this rights offering. If you use the mail, we recommend that you use
insured, registered mail, return receipt requested. If you cannot deliver
your subscription rights certificate to the subscription agent on time,
you may follow the guaranteed delivery procedures described under "The
Rights Offering--Guaranteed Delivery Procedures."
Q: May I transfer or sell my subscription rights if I do not want to purchase
any shares?
A: Yes. The subscription rights will be evidenced by transferable subscription
rights certificates. The subscription rights are transferable until the
close of business on the last trading day preceding the expiration date of
this rights offering. However, the subscription agent will only facilitate
subdivisions or transfers of the actual subscription rights certificates
until 5:00 p.m., New York City time, on , 2003, three business days
prior to the expiration date. Furthermore, the subscription rights are a
new issue of securities with no established trading market and we cannot
assure you that a market for the subscription rights will develop, or if a
market does develop, how liquid it will be. Therefore, we cannot assure
you that you will be able to sell any of your subscription rights. See
"The Rights Offering--Method of Transferring and Selling Subscription
Rights."
Q How may I sell my subscription rights?
A: You may sell your subscription rights by contacting your broker or the
institution through which you hold your Class A common stock. In addition,
if you are a record holder of our common stock, you may sell your
subscription rights through the subscription agent.
9
Q: Will I be able to trade my subscription rights on the New York Stock
Exchange?
A: Yes. We anticipate that the subscription rights will be listed for trading
on the New York Stock Exchange, or NYSE, under the symbol "REV RT" and we
expect that the subscription rights may be purchased or sold until the
close of business on the last trading day preceding the expiration date of
this rights offering.
Our Class A common stock is listed on the NYSE. On , 2003, the last
trading day before the date of this prospectus, the closing price of our
Class A common stock on the NYSE was $___ per share.
Q: What should I do if I want to participate in this rights offering or sell
my subscription rights but my shares are held in the name of my broker,
custodian bank or other nominee?
A: If you hold shares of our common stock through a broker, custodian bank or
other nominee, we will ask your broker, custodian bank or other nominee to
notify you of this rights offering. If you wish to sell or exercise your
subscription rights, you will need to have your broker, custodian bank or
other nominee act for you. To indicate your decision, you should complete
and return to your broker, custodian bank or other nominee the form
entitled "Beneficial Owner Election Form." You should receive this form
from your broker, custodian bank or other nominee with the other rights
offering materials. You should contact your broker, custodian bank or
other nominee if you do not receive this form, but you believe you are
entitled to participate in this rights offering.
Q: What should I do if I want to participate in this rights offering or sell
my subscription rights but my shares are held in the Revlon 401(k) plan?
A: If shares of our Class A common stock are held by our 401(k) plan for your
account under our 401(k) plan as of the rights offering record date, you
will be notified by us of this rights offering. If you wish to sell or
exercise some or all of your subscription rights, you will need to notify
the trustee of the 401(k) plan of your decision and the trustee will act
for you. To indicate your decision, you should properly complete and
return to the trustee by 5:00 p.m., New York City time, on , 2003
(which is seven days prior to the expiration date of this rights offering)
the form entitled "401(k) Plan Participant Election Form." If you elect to
exercise some or all of your subscription rights, you must ensure that the
total amount of the funds required for such exercise have been allocated
to an account created by you, or which you currently maintain, in the
Stable Value Fund (an existing investment election under the 401(k) plan)
no later than , 2003, seven days prior to the expiration date of this
rights offering, in order to satisfy the subscription price payable by you
upon exercise of your subscription rights. On , 2003, the trustee, to
exercise subscription rights on your behalf in the rights offering, will
transfer such funds from your Stable Value Fund account to the
subscription agent. If these funds are insufficient to exercise all of
your subscription rights in accordance with your election, the
subscription rights will be exercised to the maximum extent possible with
the amount you have invested in your Stable Value Fund account and, if an
active trading market for the rights is maintained, the trustee will
attempt to sell for your account any remaining rights that are not
exercised because of insufficient funds. You should receive the "401(k)
Plan Participant Election Form" with the other rights offering materials.
You should contact the information agent if you do not receive this form
but you believe you are entitled to participate in this rights offering
with respect to shares held for your account under the 401(k) plan.
Q: What should I do if I want to participate in this rights offering or sell
my subscription rights, but I am a stockholder with a foreign address or a
stockholder with an APO or FPO address?
A: The subscription agent will not mail subscription rights certificates to
you if you are a stockholder of record as of the rights offering record
date with an address outside the U.S. or with an Army Post Office or a
Fleet Post Office address. To exercise your subscription rights,
10
you must notify the subscription agent on or prior to 11:00 a.m., New York
City time, on , 2003 and establish to the satisfaction of the
subscription agent that you are permitted to exercise your subscription
rights under applicable law. In addition, you must take all other steps
that are necessary to exercise your subscription rights, on or prior to
the date required for participation in this rights offering. The
subscription agent will attempt to sell, if feasible, the subscription
rights held on behalf of any foreign holder who fails to notify the
subscription agent and provide acceptable instructions to it by such time
(and assuming no contrary instructions are received). The net proceeds, if
any, of any such sale, will be payable to the applicable foreign holder.
Any proceeds remaining unclaimed on the second anniversary of the
expiration date of this rights offering will be remitted to us.
Q: Will I be charged a sales commission or a fee if I exercise my subscription
rights?
A: We will not charge a brokerage commission or a fee to subscription rights
holders for exercising their subscription rights. However, if you exercise
your subscription rights through a broker, custodian bank or nominee, you
will be responsible for any fees charged by your broker, custodian bank or
nominee. If you sell your subscription rights, you will be responsible for
any commissions, taxes or brokers fees arising from any such sale. Any
sales through the subscription agent will be deemed to be effected at the
weighted average sales price of all subscription rights sold by the
subscription agent on the relevant date of sale. See "The Rights
Offering--Methods for Transfering and Selling Subscription Rights--Sale of
Subscription Rights Through the Subscription Agent."
Q: Are there any conditions to my right to exercise my subscription rights?
A: Yes. This rights offering is subject to certain limited conditions. Please
see "The Rights Offering--Conditions to the Rights Offering."
Q: What is the recommendation of your board of directors regarding this rights
offering?
A: Neither we, our board of directors nor its special committee are making any
recommendation as to whether or not you should exercise or sell your
subscription rights. You are urged to make your decision based on your own
assessment of this rights offering and after considering all of the
information in this prospectus, including the "Risk Factors" section of
this prospectus and all of the information incorporated by reference in
this prospectus. You should not view MacAndrews & Forbes' agreement to
purchase from us in a private placement the full number of shares of our
Class A common stock that it would otherwise have been entitled to
subscribe for in this rights offering in accordance with its basic
subscription privilege or to back-stop this rights offering as a
recommendation or other indication that the exercise or sale of your
subscription rights is in your best interests.
Q: How was the $____ per share subscription price established?
A: The subscription price per share for the rights offering was set by our
board of directors based on the recommendation of the special committee of
independent directors of our board of directors after negotiations between
the special committee and MacAndrews & Forbes. The board set the
subscription price at a formula equal to eighty percent (80%) of the
greater of the closing price per share of our Class A common stock on the
New York Stock Exchange on (i) the trading day before the date that our
board of directors approved this rights offering, which was $2.88 per
share, and (ii) the record date of this rights offering. In determining
the subscription price, the special committee and our board of directors
considered a number of factors, including: our need for capital; our
business prospects; the need to offer shares at a price that would be
attractive to our investors relative to the current trading price of our
Class A common stock; the historic and current market price of our Class A
common stock; general conditions in the securities market and the
difficult market conditions prevailing for the raising of equity capital;
our operating history; and the liquidity of our Class A common stock. In
conjunction with their review of these factors, the special committee also
reviewed analyses of
11
prior rights offerings by other public companies, including the range of
discounts to market value represented by the subscription prices in those
rights offerings. Based upon this review and the other factors described
above, the special committee determined that 80% represented an appropriate
discount to the market value of our Class A common stock.
Q: Is exercising my subscription rights risky?
A: The exercise of your subscription rights involves risks. Exercising your
subscription rights means buying additional shares of our Class A common
stock and should be considered as carefully as you would consider any
other equity investment. You should carefully consider the information
under the heading "Risk Factors" and all other information included or
incorporated by reference in this prospectus before deciding to exercise
or sell your subscription rights.
Q: Am I required to subscribe in this rights offering?
A: No.
Q: After I exercise my subscription rights, can I change my mind and cancel my
purchase?
A: No. Once you send in your subscription rights certificate and payment (or,
in the case of a 401(k) plan participant, once you send to the trustee the
form entitled "401(k) Plan Participant Election Form") you cannot revoke
the exercise of your subscription rights, even if the market price of our
Class A common stock is below the $___ per share subscription price. You
should not exercise your subscription rights unless you are certain that
you wish to purchase additional shares of our Class A common stock at a
price of $___ per share. However, if our 401(k) plan holds our common
stock for your account, see "The Rights Offering--Special Instructions for
Participants in Our 401(k) Plan." Subscription rights not exercised prior
to the expiration of this rights offering will have no value.
Q: What are the federal income tax consequences of exercising my subscription
rights?
A: A holder should not recognize income or loss for federal income tax
purposes in connection with the receipt or exercise of subscription rights
in this rights offering. However, you should consult with your own
financial and tax advisor. See "United States Federal Income Tax
Consequences."
Q: If this rights offering is not completed, will my subscription payment be
refunded to me?
A: Yes. The subscription agent will hold all funds it receives in escrow until
completion of this rights offering. If this rights offering is not
completed, the subscription agent will return promptly, without interest
or deduction, all subscription payments.
Q: How many shares of Class A and Class B common stock will be outstanding
after this rights offering?
A: The number of shares of Class A and Class B common stock that will be
outstanding immediately after the completion of this rights offering and
the back-stop will be 42,255,265 shares and 31,250,000 shares,
respectively. The number of shares of Class B common stock will not be
affected by this rights offering.
Q: How will this rights offering affect MacAndrews & Forbes' ownership of our
common stock?
A: As of the date of this prospectus, MacAndrews & Forbes indirectly owns
approximately 57% of our Class A common stock and 100% of our Class B
common stock, together representing approximately 83% of our combined
outstanding common stock and approximately 97% of the combined voting
power of our Class A and Class B common stock.
If no other subscription rights holders exercise their subscription rights
in this rights offering, after giving effect to MacAndrews & Forbes'
back-stop, MacAndrews & Forbes will beneficially own approximately 79% of
our outstanding Class A common stock, 100% of our outstanding Class B
common stock and approximately 98% of the combined voting power of our
Class A and Class B common stock.
12
If all subscription rights holders fully exercise their subscription
rights in this rights offering, MacAndrews & Forbes will beneficially own
approximately 70% of our outstanding Class A common stock, 100% of our
outstanding Class B common stock and approximately 97% of the combined
voting power of our Class A and Class B common stock.
Q: If I exercise my subscription rights, when will I receive shares of Class A
common stock purchased in this rights offering?
A: We will deliver to the recordholders who purchase shares in this rights
offering certificates representing the shares of our Class A common stock
purchased as soon as practicable after the expiration date of this rights
offering and after all pro rata allocations and adjustments have been
completed. We will not be able to calculate the number of shares to be
issued to each exercising holder until 5:00 p.m., New York City time, on
the third business day after the expiration date of this rights offering,
which is the latest time by which subscription rights certificates may be
delivered to the subscription agent under the guaranteed delivery
procedures described under "The Rights Offering--Guaranteed Delivery
Procedures."
Q: Who is the subscription agent for this rights offering?
A: The subscription agent is American Stock Transfer & Trust Company. The
address for delivery to the subscription agent is as follows:
By mail, hand delivery or overnight courier to:
American Stock Transfer & Trust Company
59 Maiden Lane, Plaza Level
New York, New York 10038.
Your delivery to an address or other than by the methods set forth above
will not constitute valid delivery. You may call the subscription agent at
(718) 921-8200.
Q: What should I do if I have other questions?
A: If you have questions or need assistance, please contact D.F. King & Co.,
Inc., the information agent for this rights offering, at: (800) 949-2583.
Banks and brokerage firms please call collect at: (212) 269-5550.
For a more complete description of this rights offering, see "The Rights
Offering" section included elsewhere in this prospectus.
13
RISK FACTORS
An investment in our Class A common stock involves risks. You should
carefully consider the following factors and all of the information contained
elsewhere in this prospectus and in the documents incorporated by reference
herein before deciding to exercise or sell your subscription rights.
RISKS RELATED TO THE COMPANY
We have a limited operating history under our plan and cannot assure you that
it will be successful or enable us to achieve or maintain profitable
operations.
We have recently implemented material changes in our plan intended to
improve operating results, and we are in the process of implementing the
stabilization and growth phase of our plan. We expect to experience significant
increases in sales as a result of implementing the stabilization and growth
phase of our plan. If we fail to successfully execute the stabilization and
growth phase of our plan effectively, we may not achieve expected increases in
sales, which could adversely affect our liquidity. Additionally, it is possible
that the changes may have unanticipated consequences that could be adverse to
our business. The stabilization and growth phase of our plan involves a number
of significant changes, including:
o increasing our advertising and media spending and effectiveness;
o increasing the marketing effectiveness of our wall displays to optimize
cross-selling and make the wall displays easier to merchandise, and
continuing to roll out our new wall displays which we began in 2002;
o streamlining our product assortment and reconfiguring product placement
on our wall displays;
o selectively adjusting prices on certain products;
o enhancing merchandiser coverage and working with our retail customers to
improve in-store stock levels;
o further strengthening our new product development process; and
o implementing a comprehensive program to develop and train our employees.
Each of these components of the stabilization and growth phase of our plan
carries significant risks, as well as the possibility of unexpected
consequences. Potential risks include:
o increased advertising and media expenses and our attempts to make such
advertising and media more effective may fail to achieve their intended
effects;
o our changes to our wall displays may fail to achieve their intended
effects;
o we may experience returns exceeding our expectations as a result of our
reduction of SKUs;
o we may incur costs exceeding our expectations as a result of the roll
out of our new wall displays or the new wall displays may fail to
achieve their intended effects;
o our selective price adjustments may fail to achieve their intended
effect of increasing sales of those products;
o we will incur increased costs arising from the stabilization and growth
phase of our plan to increase in-store merchandiser coverage, and the
increased merchandiser coverage may not achieve its intended effect;
o our strengthened new product development process may not be as
successful as we contemplated, and consumers may not accept our new
product offerings to the degree we envisioned;
o our competitors could increase their spending on advertising and media
and increase their new product development spending or take other steps
in response to the stabilization and
14
growth phase of our plan, which could impact the effectiveness of the
stabilization and growth phase of our plan and our ability to achieve
our objective of increased revenues and profitability over the long
term; and
o we may experience difficulties or delays in implementing a comprehensive
program to develop and train our employees.
We are a holding company with no business operations of our own and are
dependent on our subsidiaries to pay certain expenses and dividends.
We are a holding company with no business operations of our own. Our only
material asset is all of the outstanding capital stock of Products Corporation,
through which we conduct our business operations. As such, our net (loss) income
has historically consisted predominantly of our equity in the net (loss) income
of Products Corporation, which for 2000, 2001 and 2002 was approximately
$(128.0) million, $(152.2) million and $(281.8) million, respectively, which
excluded approximately $1.7 million, $1.5 million and $4.7 million,
respectively, in expenses primarily related to being a public holding company.
We will be dependent on the earnings and cash flow of, and dividends and
distributions from, Products Corporation to pay our expenses incidental to being
a public holding company. We cannot assure you that Products Corporation will
generate sufficient cash flow to pay dividends or distribute funds to us
because, for example, Products Corporation may not generate sufficient cash or
net income because of decreases in its revenues or increases in its expenses;
state laws may restrict or prohibit the issuance of dividends or making of
distributions unless Products Corporation has sufficient surplus or net profits,
which Products Corporation may not have; or contractual restrictions, including
negative covenants contained in our various debt instruments, may prohibit or
limit such dividends or distributions.
The terms of Products Corporation's existing bank credit agreement, the
12% Senior Secured Notes due 2005 (the "12% Notes"), the 9% Senior Notes due
2006 (the "9% Notes"), the 8 1/2% Senior Notes due 2006 (the "8 1/2% Notes"),
8 5/8% Senior Subordinated Notes due 2008 (the "8 5/8% Notes"), the MacAndrews &
Forbes $100 million term loan and the $40-65 million line of credit generally
restrict Products Corporation from paying dividends or making distributions,
except that Products Corporation is permitted to pay dividends and make
distributions to us, among other things, to enable us to pay expenses
incidental to being a public holding company, including, among other things,
professional fees such as legal and accounting fees, regulatory fees such as
SEC filing fees, fees associated with this filing and other miscellaneous
expenses related to being a public holding company and, subject to certain
limitations, to pay dividends or make distributions in certain circumstances to
finance the purchase by Revlon of its Class A common stock in connection with
the delivery of such Class A common stock to grantees under the Revlon, Inc.
Fourth Amended and Restated 1996 Stock Plan, or the "Stock Plan."
Our substantial indebtedness could adversely affect our operations and
flexibility, our ability to service our debt and your investment in our Class A
common stock.
We have a substantial amount of outstanding indebtedness. As of December
31, 2002, our total indebtedness was approximately $1,775.1 million. In
addition, on February 5, 2003, MacAndrews & Forbes agreed to provide Products
Corporation with the MacAndrews & Forbes $100 million term loan through
December 1, 2005. Additionally, MacAndrews & Forbes has agreed to provide
Products Corporation with the additional $40-65 million line of credit through
December 31, 2004. We anticipate that we will draw on the MacAndrew & Forbes
$100 million term loan before this rights offering is consummated in order to
continue the implementation of the stabilization and growth phase of our plan
and for general corporate purposes, although we do not currently anticipate
that we will draw on the $40-65 million line of credit during 2003.
We have substantial debt maturing in 2005 that will require refinancing,
consisting of $246.3 million (assuming the maximum amount is borrowed) under
our existing credit agreement and $363.0 million of Products Corporation's 12%
Notes, as well as amounts, if any, borrowed under the MacAndrews & Forbes $100
million term loan and the $40-65 million line of credit. We are subject to the
risks normally associated with substantial indebtedness, including the risk
that our operating
15
revenues will be insufficient to meet required payments of principal and
interest, and the risk that we will be unable to refinance existing
indebtedness when it becomes due or that the terms of any such refinancing will
be less favorable than the current terms of such indebtedness. Our substantial
indebtedness could also:
o limit our ability to fund the costs and expenses of implementing the
stabilization and growth phase of our plan, future working capital,
capital expenditures, advertising or promotional expenses, new product
development costs, purchases of wall displays, acquisitions,
investments, restructuring programs and other general corporate
requirements;
o require us to dedicate a substantial portion of our cash flow from
operations to payments on our indebtedness, thereby reducing the
availability of our cash flow for the implementation of the
stabilization and growth phase of our plan and other general corporate
purposes;
o place us at a competitive disadvantage compared to our competitors that
have less debt;
o limit our flexibility in responding to changes in our business and the
industry in which we operate; and
o make us more vulnerable in the event of adverse economic conditions or a
downturn in our business.
Restrictions and covenants in debt agreements limit our ability to take certain
actions and impose consequences in the event of failure to comply.
The indentures governing Products Corporation's outstanding indebtedness
and its existing bank credit agreement and the agreements governing the
MacAndrews & Forbes $100 million term loan and the $40-65 million line of
credit contain a number of significant restrictions and covenants that limit
our ability, among other things, to:
o borrow money;
o use assets as security in other borrowings or transactions;
o pay dividends on stock or purchase stock;
o sell assets;
o enter into certain transactions with affiliates; and
o make certain investments or acquisitions.
In addition, our existing bank credit agreement further requires us to
maintain certain financial ratios, meet certain financial tests and restricts
our ability and the ability of our subsidiaries to make capital expenditures.
These financial covenants affect our operating flexibility by, among other
things, restricting our ability to incur expenses and indebtedness that could
be used to fund the costs of implementing the stabilization and growth phase of
our plan and to grow our business, as well as to fund general corporate
purposes. For example, it was necessary to amend our existing bank credit
agreement to permit this rights offering, the MacAndrews & Forbes $100 million
term loan and the $40-65 million line of credit.
Our ability to service our debt and meet our cash requirements depends on many
factors.
We currently anticipate that operating revenue, cash on hand, funds
available for borrowing under our existing bank credit agreement and under the
MacAndrews & Forbes $100 million term loan, the proceeds from this rights
offering (which may be advanced to us as a result of the $50 million Series C
preferred stock investment prior to the consummation of this rights offering if
we have fully drawn the MacAndrews & Forbes $100 million term loan) and the
$40-65 million line of credit, will be sufficient to cover our operating
expenses, including cash requirements in connection with our operations, the
stabilization and growth phase of our plan and our debt service requirements
for 2003. The MacAndrews & Forbes $100 million term loan, the $40-65 million
line of credit and the proceeds from this rights offering are intended to help
fund the stabilization and growth phase of our plan and to decrease the risk
that would otherwise exist if we would fail to meet our debt and
16
ongoing obligations as they become due in 2003. However, if our anticipated
level of revenue growth is not achieved because of, for example, decreased
consumer spending in response to weak economic conditions or weakness in the
cosmetics category, increased competition from our competitors or because our
marketing plans are not as successful as we anticipate, or if our expenses
associated with implementation of the stabilization and growth phase of our
plan exceed the anticipated level of expenses, our current sources of funds may
be insufficient to meet our cash requirements. Additionally, in the event of a
decrease in demand for our products or reduced sales or lack of increases in
demand and sales as a result of the stabilization and growth phase of our plan,
such development, if significant, could reduce our operating revenues and could
adversely affect our ability to achieve certain financial covenants under the
credit agreement. If such funds are insufficient to cover our expenses, we
could be required to adopt one or more alternatives listed below. For example,
we could be required to:
o delay the implementation of or revise certain aspects of the
stabilization and growth phase of our plan;
o reduce or delay purchases of wall displays or advertising and
promotional expenses;
o reduce or delay capital spending;
o delay, reduce or revise restructuring programs;
o sell additional equity securities;
o sell assets or operations;
o restructure our indebtedness;
o seek additional capital contributions or loans from MacAndrews & Forbes,
our other affiliates and/or third parties; and/or
o reduce other discretionary spending.
If we are required to take any of these actions, it could have a material
adverse effect on our business, financial condition and/or results of
operations, including our ability to grow our business. In addition, we cannot
assure you that we would be able to take any of these actions because of a
variety of commercial or market factors or constraints in our debt instruments,
including, for example, the possibility that we would not reach an agreement
with our bank lenders on refinancing terms that are acceptable to us before the
waiver of certain of our financial covenants expires on January 31, 2004,
market conditions being unfavorable for an equity or debt offering, or that the
transactions may not be permitted under the terms of our various debt
instruments then in effect because of restrictions on the incurrence of debt,
incurrence of liens, asset dispositions and related party transactions. In
addition, such actions, if taken, may not enable us to satisfy our cash
requirements if the actions do not generate a sufficient amount of additional
capital. Should any such risks materialize, they could materially and adversely
affect your investment in our Class A common stock. Other than MacAndrews &
Forbes' obligations pursuant to the Investment Agreement described in this
prospectus, the MacAndrews & Forbes $100 million term loan and the $40-65
million line of credit, none of our affiliates has any obligation to contribute
or loan to us any capital.
We recently had to obtain amendments to, and waivers under, our existing credit
agreement and we expect that we will need to seek further amendments to, or
waivers of, certain covenants under our existing credit agreement in 2004.
As a result of this rights offering, the MacAndrews & Forbes $100 million
term loan, the $40-65 million line of credit and the Series C preferred stock
investment, if any, and as a result of our operating results for the fourth
quarter of 2002 and the effect of acceleration of our implementation of the
stabilization and growth phase of our plan, we recently secured waivers of
compliance with the EBITDA and leverage ratio covenants under our credit
agreement for the four quarters ended December 31, 2002 and, in light of our
expectation that the continued implementation of the stabilization and growth
phase of our plan would affect our ability to comply with these covenants
during 2003, we also secured an amendment to eliminate the EBITDA and leverage
ratio covenants
17
for the first three quarters of 2003 and a waiver of compliance with such
covenants for the four quarters ending December 31, 2003 expiring on January
31, 2004. In addition, the amendment to our credit agreement also included,
among other things, the substitution of a minimum liquidity covenant requiring
us to maintain a minimum of $20 million of liquidity from all available sources
at all times through January 31, 2004 and an amendment to increase the maximum
limit on our capital expenditures from $100 million to $115 million for 2003.
We do not expect that our operating results, including after giving effect to
various actions under the stabilization and growth phase of our plan, will
allow us to satisfy the minimum EBITDA and leverage ratio covenants for the
four consecutive fiscal quarters ending December 31, 2003. The minimum EBITDA
required to be maintained by Products Corporation under the credit agreement is
$230 million for each of the four consecutive fiscal quarters ending on
December 31, 2003 (which covenant was waived through January 31, 2004), March
31, 2004, June 30, 2004 and September 30, 2004, and $250 million for any four
consecutive fiscal quarters ending December 31, 2004 or thereafter. The
leverage ratio covenant under the credit agreement will permit a maximum ratio
of no more than 1.10:1.00 for any four consecutive fiscal quarters ending on or
after December 31, 2003 (which limit was waived through January 31, 2004 for
the four fiscal quarters ending December 31, 2003). This means that we expect
that we will need to seek a further amendment to our existing credit agreement
or waiver of such financial covenants or take one or more further actions
referred to below before January 31, 2004.
While we expect that our bank lenders will consent to such amendment or
waiver request, we cannot assure you that they will or that they will do so on
terms which are favorable to us. If we fail to secure the amendment or waiver
we could be required to take one or more of the following actions:
o refinance the existing credit agreement;
o sell additional equity securities and repay the credit agreement;
o sell assets or operations and repay the credit agreement; and/or
o seek additional capital contribution and/or loans from MacAndrews &
Forbes, our other affiliates and/or third parties and repay the credit
agreement.
In the event that we were unable to secure such a waiver or amendment and
we were not able to refinance or repay the credit agreement, our inability to
meet the financial covenants for the four consecutive fiscal quarters ending
December 31, 2003 would constitute an event of default under the credit
agreement, which would permit the bank lenders to accelerate the credit
agreement, which in turn would constitute an event of default under the
indentures governing our debt if the amount accelerated exceeds $25.0 million
and such default remains uncured within 10 days of notice from the trustee
under the applicable indenture.
We depend on our Oxford, North Carolina facility for production of a
substantial portion of our products and disruptions to this facility could
affect our sales in the U.S. and, to a lesser extent, in Latin America, Europe
and the Far East.
Following our rationalization and consolidation of our global
manufacturing, a substantial portion of our products were produced at our
Oxford, North Carolina facility. Significant unscheduled downtime at this
facility due to equipment breakdowns, power failures, natural disasters or any
other cause could adversely affect our ability to provide products to our
customers, which may affect our sales in the U.S. and, to a lesser extent, in
Latin America, Europe and the Far East. Although we maintain insurance,
including business interruption insurance, that we consider to be adequate
under the circumstances, there can be no assurance that we will not incur
losses beyond the limits or outside the coverage of our insurance.
We depend on a supply agreement with a Maesteg, Wales facility for production
of our products for the European market and loss of the agreement, or
disruption to the facility, could adversely affect our sales in Europe.
In July 2001, we sold our principal European manufacturing facility in
Maesteg, Wales and entered into a long-term supply contract with the purchaser
under which the purchaser produced
18
substantially all Revlon color cosmetics and other products for the European
market. In October 2002, after experiencing production difficulties with this
supplier, we and the supplier terminated the long-term supply agreement and
entered into a new agreement. This new agreement has significantly reduced
volume commitments and, among other things, we loaned such supplier
approximately $2.0 million and the supplier can earn performance-based payments
of approximately $6.3 million over a four-year period contingent on the
supplier achieving specific production service level objectives (of which
approximately $1.6 million was paid in March 2003). As a part of this new
arrangement, we and the supplier agreed that the manufacturing of certain
product lines would transfer from the Maesteg, Wales facility to our other
plants or other third party suppliers. If the supplier is unable to fulfill its
obligations under this new supply contract because of manufacturing
difficulties or disruption at the Maesteg, Wales facility or for any other
reason, or if we encounter difficulties in transferring certain product lines
out of the Maesteg, Wales facility to our other plants or other third party
suppliers, this could adversely affect our sales in the European market, which
could have an adverse effect on our overall results of operations and financial
condition.
We depend on a limited number of customers for a large portion of our net sales
and the loss of one or more of these customers could reduce our net sales.
For 2000, 2001 and 2002 Wal-Mart, Inc. and its affiliates accounted for
approximately 16.5%, 19.7% and 22.5%, respectively, of our net sales. We expect
that for 2003 and future periods, Wal-Mart and a small number of other
customers will, in the aggregate, account for a large portion of our net sales.
The loss of Wal-Mart or one or more of our other customers that may account for
a significant portion of our net sales, or any significant decrease in sales to
these customers or any significant decrease in our retail display space in any
of these customers' stores, could reduce our net sales and therefore could have
a material adverse effect on our business, financial condition and results of
operations.
In January 2002, Kmart Corporation filed a petition for reorganization
under Chapter 11 of the U.S. Bankruptcy Code. On January 24, 2003, Kmart
announced that it had filed its proposed plan of reorganization with the U.S.
Bankruptcy Court and, on April 30, 2003, Kmart announced that it was positioned
to emerge from bankruptcy on May 6, 2003. Throughout 2002 and continuing into
2003, Kmart continued to close underperforming stores. Kmart accounted for less
than 5% of our net sales in 2002. Although we plan to continue doing business
with Kmart for the foreseeable future and, based upon the information currently
available, believe that Kmart's bankruptcy proceedings and store closings will
not have a material adverse effect on our business, financial condition or
results of operations, there can be no assurances that further deterioration, if
any, in Kmart's financial condition will not have such an effect on us.
Competition in the consumer products business could materially adversely affect
our net sales and our market share.
The consumer products business is highly competitive. We compete on the
basis of numerous factors. Brand recognition, product quality, performance and
price, product availability at the retail stores, and the extent to which
consumers are educated on product benefits have a marked influence on
consumers' choices among competing products and brands. Advertising, promotion,
merchandising and packaging, and the timing of new product introductions and
line extensions also have a significant impact on buying decisions, and the
structure and quality of the sales force, as well as consumer consumption of
our products, affect in-store position, wall display space and inventory levels
in retail outlets. An increase in the amount of competition that we face could
have a material adverse effect on our market share. We experienced declines in
our market share in the U.S. mass-market in color cosmetics since the end of
the first half of 1998 through the first half of 2002, including a decline in
our color cosmetics market share from 32.0% in the second quarter of 1998 to
22.3% in the second quarter of 2002, and there can be no assurance that
declines in market share will not occur in the future. In addition, we compete
in selected product categories against a number of multinational manufacturers,
some of which are larger and have substantially greater resources than we do,
and which may therefore have the ability to spend more aggressively on
advertising and marketing and more flexibility to respond to changing business
and economic conditions than we do. Some of our
19
competitors have increased their spending on discounting and advertising and
promotional activities in U.S. mass-market cosmetics. In addition to products
sold in the mass-market and demonstrator-assisted channels, our products also
compete with similar products sold door-to-door or through mail-order or
telemarketing by representatives of direct sales companies.
Our foreign operations are subject to a variety of social, political and
economic risks and we may be affected by foreign currency fluctuation.
As of December 31, 2002, we had operations based in 17 foreign countries.
We are exposed to the risk of changes in social, political and economic
conditions inherent in operating in foreign countries, including those in Asia,
Eastern Europe and Latin America. Such changes include changes in the laws and
policies that govern foreign investment in countries where we have operations,
as well as, to a lesser extent, changes in U.S. laws and regulations relating
to foreign trade and investment. In addition, fluctuations in foreign currency
exchange rates may affect the results of our operations and the value of our
foreign assets, which in turn may adversely affect reported earnings and,
accordingly, the comparability of period-to-period results of operations.
During 2002, our operations in Latin America contributed 8.4% of our total net
sales, have been adversely affected by political and economic conditions and
foreign currency devaluations. Changes in currency exchange rates may affect
the relative prices at which we and foreign competitors sell products in the
same market. Our net sales outside of the U.S. and Canada for 2000, 2001 and
2002 were 38.0%, 31.9% and 32.1%, respectively, of our total net sales. In
addition, changes in the value of relevant currencies may affect the cost of
certain items required in our operations. We enter into forward foreign exchange
contracts to hedge certain cash flows denominated in foreign currency. At
December 31, 2002, the notional amount of our foreign currency forward exchange
contracts was $10.8 million. We can offer no assurances as to the future effect
of changes in social, political and economic conditions on our business, results
of operations and financial condition. Severe Acute Respiratory Syndrome, or
SARS, could have an adverse effect on our results of operations in certain
countries in our Far East region.
Terrorist attacks, such as the attacks that occurred in New York and
Washington, D.C. on September 11, 2001, and other attacks, acts of war or
military actions, such as military actions in Iraq, may adversely affect the
markets in which we operate, our operations and our profitability.
On September 11, 2001, the U.S. was the target of terrorist attacks of
unprecedented scope. These attacks have contributed to major instability in the
U.S. and other financial markets and reduced consumer confidence. These
terrorist attacks, the military response and future developments, or other
military actions, such as the recent ongoing military actions in Iraq, may
adversely affect prevailing economic conditions, resulting in reduced consumer
spending and reduced demand for our products. These developments subject our
worldwide operations to increased risks and, depending on their magnitude,
could reduce our net sales and therefore could have a material adverse effect
on our business, results of operations and financial condition.
Shares of our common stock and the capital stock of Products Corporation are
pledged to secure various of our and our affiliates' obligations and
foreclosure upon these shares could result in the acceleration of debt under
our bank credit agreement and could have other consequences.
The capital stock of Products Corporation held by us is pledged to secure
our guarantee under Products Corporation's existing bank credit agreement and
Products Corporation's 12% Notes. A foreclosure upon any shares of our or
Products Corporation's common stock could constitute a change of control under
the indenture governing the 12% Notes and the indentures governing Products
Corporation's other outstanding indebtedness. A change of control constitutes
an event of default under Products Corporation's existing bank credit
agreement, which would permit the lenders to accelerate Products Corporation's
existing bank credit agreement. In addition, holders of Products Corporation's
12% Notes, 9% Notes, 8 1/8% Notes and 8 5/8% Notes may require Products
Corporation to repurchase its notes under those circumstances. Products
Corporation may not have sufficient funds at the time of the change of control
to repay in full the borrowings under Products Corporation's existing bank
credit agreement or to repurchase the 12% Notes and the other outstanding
notes.
20
As of December 31, 2002, 4,186,104 shares of our Class A common stock
owned by REV Holdings were pledged by REV Holdings to secure $80.5 million
principal amount of REV Holdings' 12% Senior Secured Notes due 2004. From time
to time, additional shares of our Class A common stock or shares of intermediate
holding companies between us and Mafco Holdings may be pledged to secure
obligations of Mafco Holdings or its affiliates. A default under REV Holdings'
obligations which are secured by the shares pledged by REV Holdings could cause
a foreclosure with respect to such shares of our Class A common stock pledged by
REV Holdings.
Attempting to accomplish all of the elements of the stabilization and growth
phase of our plan simultaneously may prove to be burdensome and may cause
disruption or difficulties in our business.
We have recently implemented the stabilization and growth phase of our
plan, which includes increasing advertising and media spending and
effectiveness, increasing the marketing of our wall displays, including by
streamlining the number of our SKUs, selectively adjusting prices on certain
products, optimizing product availability to consumers and further
strengthening our new product development process. Attempting to accomplish all
of these elements simultaneously may prove to be a financial and operational
burden on us. If we are unable to successfully accomplish all of the elements
of the stabilization and growth phase of our plan simultaneously, it could
delay or impede our achieving our objectives of increasing revenues and could
therefore have a material adverse effect on our business, results of operations
and financial condition.
MacAndrews & Forbes has the power to direct and control our business and
Delaware law provisions and control by MacAndrews & Forbes could make a
third-party acquisition of our company difficult.
MacAndrews & Forbes currently indirectly owns approximately 83% of our
outstanding Class A and Class B common stock and controls approximately 97% of
the combined voting power of our common stock, and could own as much as 88% of
our outstanding Class A and Class B common stock and control as much as
approximately 98% of the combined voting power of our common stock after this
rights offering, assuming the back-stop is exercised in full. MacAndrews &
Forbes currently has, and after the rights offering will continue to have, the
ability to elect all of the members of our board of directors, and, after this
rights offering, will continue to be able to direct and control our policies
and those of our subsidiaries, including mergers, sales of assets and similar
transactions. Control by MacAndrews & Forbes may discourage certain types of
transactions involving an actual or potential change of control of Revlon,
including transactions in which the holders of our common stock might receive a
premium for their shares over prevailing market prices.
We are a Delaware corporation. The Delaware General Corporation Law
contains provisions that could make it more difficult for a third party to
acquire control of our company.
Future sales of our Class A common stock may depress our stock price.
No prediction can be made as to the effect, if any, that future sales of
our Class A common stock, or the availability of Class A common stock for
future sales, will have on the market price of our Class A common stock. Sales
in the public market of substantial amounts of our Class A common stock, or the
perception that such sales could occur, could adversely affect prevailing
market prices for our Class A common stock. Pursuant to the Investment
Agreement, MacAndrews & Forbes was granted registration rights with respect to
any shares of our Class A common stock that it acquires when it purchases in a
private placement the number of shares it would have otherwise been entitled to
purchase in this rights offering and under the back-stop. Pursuant to an
existing registration rights agreement, MacAndrews & Forbes has the right to
require us to register all or part of our Class A common stock owned by it and
shares of our Class A common stock issuable upon conversion of our Class B
common stock and Series B preferred stock owned by it. If MacAndrews & Forbes
exercises these registration rights and the shares that it owns are registered
and become freely tradable, the number of shares of our Class A common stock
that are available for sale will be substantially increased, which could
adversely affect the prevailing market prices for our Class A common stock.
21
RISKS RELATED TO THE RIGHTS OFFERING
Stockholders who do not fully exercise their subscription rights will have
their interests diluted by MacAndrews & Forbes and those other stockholders who
do exercise their subscription rights.
If you choose not to exercise your basic subscription right in full, your
relative ownership interest in us will be diluted to the extent other
stockholders exercise their basic subscription and over-subscription rights.
This rights offering and the private placement of shares to MacAndrews & Forbes
will result in our issuance of an additional 21,739,130 shares of our Class A
common stock. In addition, although MacAndrews & Forbes has agreed not to
exercise its over-subscription right, it has committed to back-stop this rights
offering by purchasing, in a private placement from us, all of the shares of
Class A common stock that are not purchased by other stockholders in this rights
offering, which would increase their overall ownership position. If no
subscription rights holders other than MacAndrews & Forbes exercise their
subscription rights in this rights offering, the transactions contemplated by
the Investment Agreement, including the MacAndrews & Forbes back-stop, will
result in the issuance of an additional 21,739,130 shares of our Class A common
stock to MacAndrews & Forbes. Subscription rights holders who do not exercise or
sell their subscription rights will lose any value in their subscription rights.
The subscription price determined for this rights offering is not an indication
of our value.
The subscription price per share for the rights offering was set by our
board of directors based on the recommendation of the special committee of
independent directors of our board of directors after negotiations between the
special committee and MacAndrews & Forbes. The board set the subscription price
at a formula equal to eighty percent (80%) of the greater of the closing price
per share of our Class A common stock on the New York Stock Exchange on (i) the
trading day before the date that our board of directors approved this rights
offering, which was $2.88 per share, and (ii) the record date for this rights
offering. In determining the subscription price, the special committee and our
board of directors considered a number of factors, including: our need for
capital; our business prospects; the need to offer shares at a price that would
be attractive to our investors relative to the current trading price of our
Class A common stock; the historic and current market price of our Class A
common stock; general conditions in the securities market and the difficult
market conditions prevailing for the raising of equity capital; our operating
history; and the liquidity of our Class A common stock. In conjunction with
their review of these factors, the special committee also reviewed analyses of
prior rights offerings by other public companies, including the range of
discounts to market value represented by the subscription prices in those
rights offerings. Based upon this review and other factors described above, the
special committee determined that 80% represented an appropriate discount to the
market value of our Class A common stock. The subscription price does not
necessarily bear any relationship to the book value of our assets, past
operations, cash flows, losses, financial condition or any other established
criteria for value. You should not consider the subscription price as an
indication of the value of our Class A common stock. After the date of this
prospectus, our Class A common stock may trade at prices above or below the
subscription price.
You may not revoke your subscription exercise and could be committed to buying
shares above the prevailing market price.
Once you exercise your subscription rights, you may not revoke the
exercise. The public trading market price of our Class A common stock may
decline before the subscription rights expire. If you exercise your
subscription rights and, afterwards, the public trading market price of our
Class A common stock decreases below the subscription price, you will have
committed to buying shares of our Class A common stock at a price above the
prevailing market price. Our Class A common stock is traded on the NYSE under
the symbol "REV" and the last reported sales price of our Class A common stock
on the NYSE on May 1, 2003 was $3.15 per share. Moreover, you may be unable
to sell your shares of Class A common stock at a price equal to or greater than
the subscription price you paid for such shares.
22
If we cancel this rights offering, neither we nor the subscription agent will
have any obligation to you except to return your subscription payments.
If we elect to withdraw or terminate this rights offering, neither we nor
the subscription agent will have any obligation with respect to the
subscription rights except to return, without interest or deduction, any
subscription payments we or the subscription agent received from you.
If you do not act promptly and follow subscription instructions, your exercise
of subscription rights may be rejected.
Stockholders who desire to purchase shares in this rights offering must
act promptly to ensure that all required forms and payments are actually
received by the subscription agent prior to , 2003, the expiration date of this
rights offering. If you are a beneficial owner of shares, you must act promptly
to ensure that your broker, custodian bank or other nominee acts for you and
that all required forms and payments are actually received by the subscription
agent prior to , 2003. We shall not be responsible if your broker, custodian or
nominee fails to ensure that all required forms and payments are actually
received by the subscription agent prior to the , 2003 expiration date of this
rights offering. If you fail to complete and sign the required subscription
forms, send an incorrect payment amount, or otherwise fail to follow the
subscription procedures that apply to your exercise in this rights offering, the
subscription agent may, depending on the circumstances, reject your subscription
or accept it only to the extent of the payment received. Neither we nor our
subscription agent undertakes to contact you concerning an incomplete or
incorrect subscription form or payment, nor are we under any obligation to
correct such forms or payment. We have the sole discretion to determine whether
a subscription exercise properly follows the subscription procedures.
If you are a participant in our 401(k) plan, you must act promptly to
ensure that all required forms are received by the trustee and that the total
amount of the funds required for an exercise of your subscription rights have
been allocated to an account created by you, or which you currently maintain, in
the Stable Value Fund no later than ___, 2003, which is seven days prior to the
expiration date of this rights offering. See "The Rights Offering--Special
Instructions for Participants in Our 401(k) Plan."
No prior market exists for the subscription rights.
The subscription rights are a new issue of securities with no established
trading market and we cannot assure you that a market for the subscription
rights will develop or, if a market does develop, as to how liquid it will be.
The subscription rights are transferable until the close of business on the last
trading day prior to the expiration date of this rights offering, at which time
they will cease to have any value. If you wish to sell your subscription rights
or the subscription agent or trustee tries to sell subscription rights on your
behalf in accordance with the procedures discussed in this prospectus but such
rights cannot be sold, and either you subsequently provide the subscription
agent or trustee with instructions to exercise the subscription rights and your
instructions are not timely received by the subscription agent or trustee or you
do not provide any instructions to exercise your subscription rights, then the
subscription rights will expire and will have no further value.
If you make payment of the subscription price by personal check, your check
may not have cleared in sufficient time to enable you to purchase shares in this
rights offering.
Any personal check used to pay for shares to be issued in this rights
offering must clear prior to the expiration date of this rights offering, and
the clearing process may require five or more business days. If you choose to
exercise your subscription rights, in whole or in part, and to pay for shares by
personal check and your check has not cleared prior to the expiration date of
this rights offering, you will not have satisfied the conditions to exercise
your subscription rights and will not receive the shares you attempted to
purchase and you will lose the value of your subscription rights.
23
FORWARD-LOOKING STATEMENTS
This prospectus contains forward-looking statements that involve risks and
uncertainties. Our actual results may differ materially from those discussed in
such forward-looking statements. Such statements include, without limitation,
our expectations and estimates (whether qualitative or quantitative) as to:
o increases of our advertising and media spending, as well as improving
the effectiveness of our advertising;
o the introduction of new products and further strengthening of our new
product development process;
o our plans to update our retail presence and improve the marketing
effectiveness of our retail wall displays by installing
newly-reconfigured wall displays and reconfiguring existing wall
displays at our retail customers (and our estimates of the costs of such
wall displays, the effects of such plans on the accelerated amortization
of existing wall displays and the estimated amount of such
amortization);
o our plans to streamline our product assortment and reconfigure product
placement on our wall displays, selectively adjust prices on certain of
our products and improve customers' stock levels by enhancing
merchandiser coverage and reducing damages by continuing to develop our
tamper evident program;
o our plans to implement comprehensive programs to develop and train our
employees;
o our future financial performance;
o the effect on sales of political and/or economic conditions, adverse
currency fluctuations, military actions and competitive activities;
o our plans to accelerate the implementation of the stabilization and
growth phase of our plan and the charges and the cash costs resulting
from implementing such plan and the timing of such costs as well as our
expectations to capitalize on the actions taken during the stabilization
and growth phase of our plan with the objective of increasing our
revenues and profitability over the long term;
o restructuring activities, restructuring costs, and benefits from such
activities;
o our expectation that operating revenues, cash on hand, cash available
from this rights offering and the $50 million Series C preferred stock
investment, if any, and availability of borrowings under the MacAndrews
& Forbes $100 million term loan, the $40-65 million line of credit, and
our existing bank credit agreement, will be sufficient to satisfy our
cash requirements in 2003, the availability of funds from restructuring
indebtedness, selling assets or operations, capital contributions or
loans from MacAndrews & Forbes, our other affiliates and/or third
parties and the sale of additional shares of our common stock, and our
expectation that we will not require MacAndrews & Forbes to make the $50
million Series C preferred stock investment and that we will not draw on
the $40-65 million line of credit during 2003;
o uses of funds, including amounts required for implementing the
stabilization and growth phase of our plan, including the purchase and
reconfiguration of wall displays (including by streamlining our product
assortment), increases in advertising and media, selectively adjusting
prices on certain SKUs and our estimates of operating expenses, working
capital expenses, wall display costs, capital expenditures,
restructuring costs and debt service payments;
o the effects of the loss of one or more customers, including, without
limitation, Wal-Mart, and the status of our relationship with our
customers;
o the effects of competitive responses to the implementation of the
stabilization and growth phase of our plan;
24
o our ability to effectively execute the various elements of the
stabilization and growth phase of our plan;
o our plan to refinance our debt maturing in 2005;
o our plan to secure a further waiver or amendment of our credit
agreement, including the EBITDA and leverage ratio covenants or
refinancing or to repay such debt before January 31, 2004, if such
amendment or waiver is not secured; and
o our ability to consummate the rights offering and the timing thereof.
In addition, the documents incorporated in this prospectus by reference
contain other forward-looking statements. Statements that are not historical
facts, including statements about our beliefs and expectations, are
forward-looking statements. Forward-looking statements can be identified by,
among other things, the use of forward-looking language, such as "believes,"
"expects," "estimates," "projects," "forecast," "may," "will," "should,"
"seeks," "plans," "scheduled to," "anticipates" or "intends" or the negative of
those terms, or other variations of those terms or comparable language, or by
discussions of strategy or intentions. A number of important factors could
cause actual results to differ materially from those contained in any
forward-looking statement. In addition to factors that may be described in our
filings with the SEC, including this filing, the following factors, among
others, could cause our actual results to differ materially from those
expressed in any forward-looking statements made by us:
o difficulties or delays in developing and/or presenting our increased
advertising programs and/or improving the effectiveness of our
advertising;
o difficulties or delays in developing and introducing new products or
failure of customers to accept new product offerings and/or in further
strengthening our new product development process;
o difficulties or delays or unanticipated costs associated with improving
the marketing effectiveness of our wall displays;
o difficulties or delays in implementing our plans to streamline our
product assortment and reconfigure product placement on our wall
displays, adjust prices of our products and/or improve customers' stock
levels by enhancing merchandiser coverage and reducing damages by
continuing to develop our tamper evident program;
o difficulties or delays in implementing comprehensive programs to develop
and train our employees;
o unanticipated circumstances or results affecting our financial
performance, including changes in consumer preferences, such as reduced
consumer demand for our color cosmetics and other current products, and
actions by competitors, including business combinations, technological
breakthroughs, new products offerings, promotional spending and
marketing and promotional successes, including increases in market
share;
o effects of and changes in political and/or economic conditions,
including inflation, monetary conditions and military actions, and in
trade, monetary, fiscal and tax policies in international markets;
o unanticipated costs or difficulties or delays in completing projects
associated with the stabilization and growth phase of our plan or
difficulties or delays in capitalizing on the actions taken during the
stabilization and growth phase of our plan to increase our revenues and
profitability over the long term;
o difficulties, delays or unanticipated costs or less than expected
savings and other benefits resulting from our restructuring activities;
o lower than expected operating revenues, the inability to secure capital
contributions or loans from MacAndrews & Forbes, our other affiliates
and/or third parties or the unavailability of
25
funds under our existing bank credit agreement, the MacAndrews & Forbes
$100 million term loan, the $50 million Series C preferred stock
investment, if any, the $40-65 million line of credit, if any, from
restructuring indebtedness, selling assets or operations or the sale of
additional shares of our common stock or our cash flow requirements
differing from our expectations that would require us to have MacAndrews
& Forbes make the $50 million Series C preferred stock investment and/or
require us to draw on some or all of the $40-65 million line of credit
or from this rights offering;
o higher than expected operating expenses, working capital expenses, wall
display costs, capital expenditures, restructuring costs or debt service
payments;
o combinations among significant customers or the loss, insolvency or
failure to pay debts by a significant customer or customers;
o difficulties or delays in responding to competitive responses to the
implementation of the stabilization and growth phase of our plan;
o difficulties, delays or unanticipated costs in the execution of elements
of the stabilization and growth phase of our plan;
o an inability to refinance our debt maturing in 2005;
o difficulties in, or an inability to execute, our plan to secure a
further waiver or amendment of our credit agreement; and
o difficulties or delays in consummating this rights offering.
You should consider the areas of risk described above, as well as those
set forth in other documents we have filed with the SEC and which are
incorporated by reference into this prospectus, in connection with any
forward-looking statements that may be made by us. Forward-looking statements
speak only as of the date they are made, and, except for our ongoing
obligations to disclose material information under the federal securities laws,
we undertake no obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or otherwise. You are
advised, however, to consult any additional disclosures we make in our
Quarterly Reports on Form 10-Q, Annual Report on Form 10-K and Current Reports
on Form 8-K to the SEC (which, among other places, can be found on the SEC's
website at http://www.sec.gov, as well as on our website at
http://www.revloninc.com.) See "Where You Can Find More Information." The
cautionary discussion of risks and uncertainties under "Risk Factors" are
factors that we think could cause our actual results to differ materially from
expected results. Factors other than those listed above could cause our results
to differ materially from expected results. This discussion is provided as
permitted by the Private Securities Litigation Reform Act of 1995.
26
UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL DATA
The following sets forth the historical consolidated financial data for
the year ended December 31, 2002, as adjusted to give pro forma effect to this
rights offering and amendments to the credit agreement, the MacAndrews & Forbes
$100 million term loan and the $40-65 million line of credit as if such
transactions had been consummated on January 1, 2002, and balance sheet data as
of December 31, 2002, as adjusted to give pro forma effect to the rights
offering and amendments to the credit agreement, the MacAndrews & Forbes $100
million term loan and the $40-65 million line of credit as if such transactions
had occurred on December 31, 2002. The pro forma adjustments are based upon
available information and certain assumptions that management believes are
reasonable. The pro forma financial data do not purport to represent our
results of operations or our financial position that actually would have
occurred had such transactions been consummated on the aforesaid dates.
The financial data should be read in conjunction with our consolidated
financial statements and the notes to those financial statements included in
the documents incorporated by reference in this prospectus.
YEAR ENDED DECEMBER 31, 2002
-------------------------------------------------------------
ACTUAL ADJUSTMENTS AS ADJUSTED
------------------- ----------------- -----------------------
(DOLLARS IN MILLIONS, EXCEPT PER SHARE AMOUNTS)
STATEMENT OF OPERATIONS DATA (a):
Operating loss ................................... $ (114.9) $ (114.9)
Interest expense, net ............................ 155.5 $ 13.4 168.9
Net loss ......................................... (286.5) (14.7) (301.2)
Weighted average number of shares outstanding .... 52,199,468 21,739,130 73,938,598 (b)
Basic and diluted loss per common share .......... $ (5.49)(c) $ (4.07)(b)
BALANCE SHEET DATA (d):
Total assets ..................................... $ 939.5 $ 147.4 $ 1,086.9
Total indebtedness ............................... 1,775.1 100.0 1,875.1
Total stockholders' deficiency ................... (1,640.8) 47.4 (1,593.4)
(a) Pro forma results reflect the increase in interest expense of $13.4 million
or $0.18 pro forma basic and diluted loss per common share and the
incremental amortization of debt issuance costs of $1.3 million or $0.02
pro forma basic and diluted loss per common share for the year ended
December 31, 2002, as if the amendments to the credit agreement, the
MacAndrews and Forbes $100 million term loan and the $40-65 million line of
credit were entered into on January 1, 2002.
The $40-65 million line of credit is not assumed to be drawn for pro forma
purposes, nor is the $50 million Series C preferred stock investment
expected to be advanced. Therefore, no adjustments to pro forma net loss
and pro forma basic and diluted net loss per common share are reflected for
the year ended December 31, 2002. Additionally, no adjustments to pro forma
net loss and pro forma basic and diluted net loss per common share are
reflected for $0.4 million of certain costs associated with the amendments
to the credit agreement that will be charged to expense as incurred.
(b) Pro forma weighted average number of shares outstanding and pro forma basic
and diluted loss per common share reflect the issuance of 21,739,130 shares
of Class A common stock pursuant to this rights offering and the private
placement of shares to MacAndrews & Forbes issued at an assumed
subscription price of $2.30 per share (which represents 80% of the closing
price per share of our Class A common stock on the NYSE on January 30,
2003, the trading day before the date that our board of directors approved
this rights offering). If the subscription price on the record date of this
rights offering were $2.45, which represents 80% of the highest closing
price per share of our Class A common stock on the NYSE in the 30-day
period prior to
27
April 25, 2003, the pro forma weighted average number of shares
outstanding would be 72,607,631 and the pro forma basic and diluted loss
per common share would be $4.15.
(c) If at the time of the consummation of this rights offering, the fair value
of our shares is more than the subscription price determined pursuant to
the formula described on page 9, basic and diluted loss per common share
will be restated for all prior periods, similar to a stock dividend. As a
result, the weighted average number of shares outstanding would increase by
approximately 6% and the basic and diluted loss per common share would
decrease by approximately 6% for the year ended December 31, 2002.
(d) The pro forma balance sheet as of December 31, 2002 reflects the MacAndrews
& Forbes $100 million term loan and net proceeds of $47.4 million for the
issuance of shares of our common stock pursuant to this rights offering.
We do not currently anticipate that the $40-65 million line of credit will
be drawn in 2003 or that we will require the $50 million Series C preferred
stock investment based upon our expectation that the rights offering will
be consummated in the second quarter of 2003. Therefore, no adjustments to
the pro forma balance sheet are reflected as of December 31, 2002.
28
THE RIGHTS OFFERING
REASONS FOR THE RIGHTS OFFERING
On February 5, 2003, we announced that our board of directors, at the
recommendation of its special committee of independent directors, had discussed
and authorized:
o the MacAndrews & Forbes $100 million term loan, the $50 million Series C
preferred stock investment, if any, and the $40-65 million line of
credit from MacAndrews & Forbes to Products Corporation;
o the commencement of this rights offering; and
o the Investment Agreement under which MacAndrews & Forbes agreed to take
certain actions with regard to this rights offering, including, without
limitation, its agreement to make the $50 million Series C preferred
stock investment if, prior to closing this rights offering, we have
fully drawn the MacAndrews & Forbes $100 million term loan.
This rights offering is being made in connection with the stabilization
and growth phase of our plan, which involves, among other things, increasing
advertising and media spending, making certain changes to our new in-store wall
displays and reconfiguring existing wall displays at our retail accounts,
streamlining the number of our SKUs, selectively adjusting prices on certain
products, optimizing product availability to consumers and further
strengthening our new product development process. If this rights offering is
canceled, any funds we or the subscription agent have received from you will be
promptly refunded, without interest or deduction.
In reaching its conclusion, our board of directors considered a number of
factors, including:
o our needs for cash to help fund a portion of the costs and expenses of
the stabilization and growth phase of our plan and to help satisfy
anticipated obligations arising from the implementation of such plan;
o the opportunity that this rights offering allows all of our stockholders
on the rights offering record date to participate and acquire additional
shares of our Class A common stock at a discount to the market price or,
alternatively, to realize value from the sale of the subscription rights
if a stockholder does not have the means or the interest in exercising
the subscription rights;
o concerns as to the availability of other financing alternatives, in
light of the difficulties faced by the company in raising equity capital
or debt on terms as favorable as the MacAndrews & Forbes proposal in
light of the current state of the capital markets and our business;
o the subscription price relative to our Class A common stock's historical
and recent trading price and pricing policies customary for transactions
of this type;
o MacAndrews & Forbes' willingness to purchase in a private placement the
full number of shares of our Class A common stock it would otherwise
have been entitled to subscribe for in this rights offering in
accordance with its basic subscription privilege and to purchase all of
the shares of our Class A common stock not subscribed for by our other
stockholders pursuant to their basic subscription privileges and their
over-subscription privileges, which ensured that the maximum of $50
million would be raised in this rights offering, as well as its
willingness to subordinate its over-subscription rights that it
otherwise would be entitled to exercise in order to enhance the
over-subscription privileges of our other stockholders;
o the potential impact of this rights offering on relative voting and
ownership interests of our stockholders as described under "--Effects of
Rights Offering on the MacAndrews & Forbes' Securities and Ownership"
included elsewhere in this prospectus; and
o the potential tax consequences of this rights offering.
Neither our board of directors nor its special committee is making any
recommendation as to whether or not you should exercise or sell your
subscription rights.
29
THE RIGHTS
We will distribute to each holder of our Class A and Class B common stock
who is a record holder of our Class A and Class B common stock on the rights
offering record date, which is 5:00 p.m., New York City time, on ,
2003, at no charge, one transferable subscription right for each shares of
Class A and Class B common stock owned, for a total of approximately
subscription rights. The subscription rights will be evidenced by transferable
subscription rights certificates. Each subscription right will allow you to
purchase one share of our Class A common stock at a price of $ . If you
elect to exercise your basic subscription privilege in full, you may also
subscribe, at the subscription price, for additional shares of our Class A
common stock under your over-subscription privilege to the extent that other
rights holders (except MacAndrews & Forbes) do not exercise their basic
subscription privileges in full. If a sufficient number of shares of our Class
A common stock is unavailable to fully satisfy the over-subscription privilege
requests, the available shares of Class A common stock will be sold pro rata
among subscription rights holders who exercised their over-subscription
privilege based on the number of shares each subscription rights holder
subscribed for under the basic subscription privilege. MacAndrews & Forbes has
agreed not to exercise its over-subscription privilege in order to enhance the
over-subscription privileges of our other Class A common stockholders. We have
not engaged an underwriter in connection with this rights offering.
If you hold your shares in a brokerage account or through a dealer or
other nominee, please see the information included below the heading
"--Beneficial Owners." If our 401(k) plan holds shares of our common stock for
your account, please see the information included below the heading "--Special
Instructions for Participants in our 401(k) Plan."
NO FRACTIONAL RIGHTS
We will not issue fractional subscription rights or cash in lieu of
fractional subscription rights. Fractional subscription rights will be rounded
down to the nearest whole number, with such adjustments as may be necessary to
ensure that we will receive gross proceeds of $50 million from this rights
offering.
You may request that the subscription agent divide your subscription
rights certificate into transferable parts, for instance, if you are the record
holder for a number of beneficial holders of our common stock. However, the
subscription agent will not divide your subscription rights certificate so that
you would receive any fractional subscription rights. The subscription agent
will only facilitate subdivisions or transfers of subscription rights
certificates until 5:00 p.m., New York City time, on , 2003, three
business days prior to the expiration date.
EXPIRATION OF THE RIGHTS OFFERING AND EXTENSIONS, AMENDMENTS AND TERMINATION
You may exercise your subscription rights at any time before 5:00 p.m.,
New York City time, on , 2003, the expiration date for this rights
offering. We may, in our sole discretion, extend the time for exercising the
subscription rights. If the commencement of this rights offering is delayed for
a period of time, the expiration date of this rights offering will be similarly
extended.
We will extend the duration of the rights offering as required by
applicable law, and may choose to extend it if we decide that changes in the
market price of our Class A common stock warrant an extension or if we decide
to give investors more time to exercise their subscription rights in this
rights offering. However, because MacAndrews & Forbes has agreed to back-stop
this rights offering, we will not need to extend the exercise period because
the back-stop arrangement ensures that we will receive total gross proceeds of
$50 million. We may extend the expiration date of this rights offering by
giving oral or written notice to the subscription agent and information agent
on or before the
30
scheduled expiration date. If we elect to extend the expiration of this rights
offering, we will issue a press release announcing such extension no later than
9:00 a.m., New York City time, on the next business day after the most recently
announced expiration date.
We reserve the right, in our sole discretion, to amend or modify the terms
of this rights offering.
If you do not exercise your subscription rights before the expiration date
of this rights offering, your unexercised subscription rights will be null and
void and will have no value. We will not be obligated to honor your exercise of
subscription rights if the subscription agent receives the documents relating
to your exercise after this rights offering expires, regardless of when you
transmitted the documents, except if you have timely transmitted the documents
under the guaranteed delivery procedures described below.
SUBSCRIPTION PRIVILEGES
Your subscription rights entitle you to a basic subscription privilege and
an over-subscription privilege.
Basic Subscription Privilege. With your basic subscription privilege, you
may purchase one share of our Class A common stock per subscription right, upon
delivery of the required documents and payment of the subscription price of
$ per share. You are not required to exercise all of your subscription
rights unless you wish to purchase shares under your over-subscription
privilege. We will deliver to the recordholders who purchase shares in this
rights offering certificates representing the shares purchased with a holder's
basic subscription privilege as soon as practicable after this rights offering
has expired.
Over-Subscription Privilege. In addition to your basic subscription
privilege, you may subscribe for additional shares of our Class A common stock,
upon delivery of the required documents and payment of the subscription price
of $ per share, before the expiration of this rights offering. You may only
exercise your over-subscription privilege if you exercised your basic
subscription privilege in full and other holders of subscription rights (except
MacAndrew & Forbes) do not exercise their basic subscription privileges in
full.
Pro Rata Allocation. If there are not enough shares of our Class A common
stock to satisfy all subscriptions made under the over-subscription privilege,
we will allocate the remaining shares of our Class A common stock pro rata,
after eliminating all fractional shares, among those over-subscribing rights
holders. "Pro rata" means in proportion to the number of shares of our Class A
common stock that you and the other subscription rights holders have purchased
by exercising your basic subscription privileges. If there is a pro rata
allocation of the remaining shares of our Class A common stock and you receive
an allocation of a greater number of shares than you subscribed for under your
over-subscription privilege, then we will allocate to you only the number of
shares for which you subscribed. We will allocate the remaining shares among
all other holders exercising their over-subscription privileges.
MacAndrews & Forbes will not be allocated any additional shares of our
Class A common stock as part of its over-subscription privilege because it has
agreed in the Investment Agreement not to exercise its over-subscription
privilege.
Full Exercise of Basic Subscription Privilege. You may exercise your
over-subscription privilege only if you exercise your basic subscription
privilege in full. To determine if you have fully exercised your basic
subscription privilege, we will consider only the basic subscription privileges
held by you in the same capacity. For example, suppose that you were granted
subscription rights for shares of our Class A common stock that you own
individually and shares of our Class A common stock that you own collectively
with your spouse. If you wish to exercise your over-subscription privilege with
respect to the subscription rights you own individually, but not with respect
to the subscription rights you own collectively with your spouse, you only need
to fully exercise your basic subscription privilege with respect to your
individually owned subscription rights. You do not have to subscribe for any
shares under the basic subscription privilege owned collectively with your
spouse to exercise your individual over-subscription privilege.
31
When you complete the portion of your subscription rights certificate to
exercise your over-subscription privilege, you will be representing and
certifying that you have fully exercised your subscription privileges as to
shares of our Class A common stock that you hold in that capacity. You must
exercise your over-subscription privilege at the same time you exercise your
basic subscription privilege in full.
Return of Excess Payment. If you exercised your over-subscription
privilege and are allocated less than all of the shares of our Class A common
stock for which you wished to subscribe, your excess payment for shares that
were not allocated to you will be returned to you by mail, without interest or
deduction, as soon as practicable after the expiration date of this rights
offering. We will deliver to the recordholders who purchase shares in this
rights offering certificates representing the shares of our Class A common
stock that you purchased as soon as practicable after the expiration date of
this rights offering and after all pro rata allocations and adjustments have
been completed.
If you are a participant in our 401(k) plan, all subscription payments
received by the subscription agent from the trustee on your behalf and not
applied to the purchase of shares of our Class A common stock will be returned
to your Stable Value Fund account established under the 401(k) plan, without
interest or deduction, where the funds will remain subject to your further
investment directions in accordance with the terms of the 401(k) plan.
CONDITIONS TO THIS RIGHTS OFFERING
We may terminate this rights offering, in whole or in part, if at any time
before completion of this rights offering there is any judgment, order, decree,
injunction, statute, law or regulation entered, enacted, amended or held to be
applicable to this rights offering that in the sole judgment of our board of
directors would or might make this rights offering or its completion, whether
in whole or in part, illegal or otherwise restrict or prohibit completion of
this rights offering. We may waive any of these conditions and choose to
proceed with this rights offering even if one or more of these events occur. If
we terminate this rights offering, in whole or in part, all affected
subscription rights will expire without value and all subscription payments
received by the subscription agent will be returned promptly, without interest
or deduction. See also "--Cancellation Rights."
METHOD OF SUBSCRIPTION--EXERCISE OF RIGHTS
You may exercise your subscription rights by delivering the following to
the subscription agent, at or prior to 5:00 p.m., New York City time, on
, 2003, the expiration date of this rights offering:
o Your properly completed and executed subscription rights certificate
with any required signature guarantees or other supplemental
documentation; and
o Your full subscription price payment for each share subscribed for under
your subscription privileges.
If you are a beneficial owner of shares of our common stock whose shares
are registered in the name of a broker, custodian bank or other nominee, you
should instruct your broker, custodian bank or other nominee to exercise your
rights and deliver all documents and payment on your behalf prior to 5:00 p.m.
New York City time on , 2003, the expiration date of this rights
offering.
Your subscription rights will not be considered exercised unless the
subscription agent receives from you, your broker, custodian or nominee, as the
case may be, all of the required documents and your full subscription price
payment prior to 5:00 p.m., New York City time, on , 2003, the
expiration date of this rights offering.
If you are a participant in our 401(k) plan, please refer to the
information set out in "--Special Instructions for Participants in Our 401(k)
Plan."
METHOD OF PAYMENT
Your payment of the subscription price must be made in U.S. dollars for
the full number of shares of Class A common stock for which you are subscribing
by either:
32
o check or bank draft drawn upon a U.S. bank or postal, telegraphic or
express money order payable to the subscription agent; or
o wire transfer of immediately available funds, to the subscription
account maintained by the subscription agent at JPMorgan Chase Bank, ABA
No. 021 000 021, Account No. 323-113109.
If you are a participant in our 401(k) plan, please refer to the
information set out in "--Special Instructions for Participants in Our 401(k)
Plan."
RECEIPT OF PAYMENT
Your payment will be considered received by the subscription agent only
upon:
o Clearance of any uncertified check;
o Receipt by the subscription agent of any certified check or bank draft
drawn upon a U.S. bank or of any postal, telegraphic or express money
order; or
o Receipt of collected funds in the subscription account designated above.
CLEARANCE OF UNCERTIFIED CHECKS
If you are paying by uncertified personal check, please note that
uncertified checks may take at least five (5) business days to clear. If you
wish to pay the subscription price by uncertified personal check, we urge you
to make payment sufficiently in advance of the time this rights offering
expires to ensure that your payment is received by the subscription agent and
clears by the rights offering expiration date. We urge you to consider using a
certified or cashier's check, money order or wire transfer of funds to avoid
missing the opportunity to exercise your subscription rights should you decide
to exercise your subscription rights.
DELIVERY OF SUBSCRIPTION MATERIALS AND PAYMENT
You should deliver your subscription rights certificate and payment of the
subscription price or, if applicable, notices of guaranteed delivery, to the
subscription agent by one of the methods described below:
By mail, hand delivery or overnight courier to:
AMERICAN STOCK TRANSFER & TRUST COMPANY
59 Maiden Lane, Plaza Level
New York, NY 10038
You may call the subscription agent at (718) 921-8200.
Your delivery to an address or by any method other than as set forth above
will not constitute valid delivery.
CALCULATION OF SUBSCRIPTION RIGHTS EXERCISED
If you do not indicate the number of subscription rights being exercised,
or do not forward full payment of the total subscription price payment for the
number of subscription rights that you indicate are being exercised, then you
will be deemed to have exercised your basic subscription privilege with respect
to the maximum number of subscription rights that may be exercised with the
aggregate subscription price payment you delivered to the subscription agent.
If your aggregate subscription price payment is greater than the amount you owe
for your subscription, you will be deemed to have exercised your
over-subscription privilege to purchase the maximum number of shares of our
Class A common stock with your over-payment. If we do not apply your full
subscription price payment to your purchase of shares of our Class A common
stock, we or the subscription agent will return the excess amount to you by
mail, without interest or deduction, as soon as practicable after the
expiration date of this rights offering. If you are a participant in our 401(k)
plan, all subscription payments received by the subscription agent from the
trustee on your behalf and not applied to the
33
purchase of shares of our Class A common stock will be returned to your Stable
Value Fund account established under the 401(k) plan, without interest or
deduction, where the funds will remain subject to your further investment
directions in accordance with the terms of the 401(k) plan.
EXERCISING A PORTION OF YOUR SUBSCRIPTION RIGHTS
If you subscribe for fewer than all of the shares of our Class A common
stock represented by your subscription rights certificate, you may request from
the subscription agent a new subscription rights certificate representing your
unused subscription rights and then attempt to sell your unused subscription
rights. See "--Method of Transferring and Selling Subscription Rights."
Alternatively, you may transfer a portion of your subscription rights and
request from the subscription agent a new subscription rights certificate
representing the rights you did not transfer. HOWEVER, THE SUBSCRIPTION AGENT
WILL ONLY FACILITATE SUBDIVISIONS OR TRANSFERS OF SUBSCRIPTION RIGHTS
CERTIFICATES UNTIL 5:00 P.M., NEW YORK CITY TIME, ON , 2003, THREE
BUSINESS DAYS PRIOR TO THE EXPIRATION DATE. All subscription rights must be
exercised prior to the expiration date of this rights offering, or else your
subscription rights will be null and void. We will not issue any subscription
rights certificates for unexercised subscription rights after the rights
offering expiration date.
If you are a participant in our 401(k) plan, please refer to the
information set out in "--Special Instructions for Participants in Our 401(k)
Plan."
YOUR FUNDS WILL BE HELD BY THE SUBSCRIPTION AGENT UNTIL SHARES OF OUR CLASS A
COMMON STOCK ARE ISSUED
The subscription agent will hold your payment of the subscription price in
a segregated account with other payments received from other subscription
rights holders until we issue your shares of our Class A common stock to you
upon consummation of the rights offering.
MEDALLION GUARANTEE MAY BE REQUIRED
Your signature on each subscription rights certificate must be guaranteed
by an eligible institution, such as a member firm of a registered national
securities exchange or a member of the National Association of Securities
Dealers, Inc., or a commercial bank or trust company having an office or
correspondent in the U.S., subject to standards and procedures adopted by the
subscription agent, unless:
o Your subscription rights certificate provides that shares are to be
delivered to you as record holder of those subscription rights; or
o You are an eligible institution.
NOTICE TO BENEFICIAL HOLDERS
If you are a broker, a trustee or a depositary for securities who holds
shares of our common stock for the account of others on , 2003, the
rights offering record date, you should notify the respective beneficial owners
of such shares of this rights offering as soon as possible to find out their
intentions with respect to exercising or selling their subscription rights. You
should obtain instructions from the beneficial owner with respect to their
subscription rights, as set forth in the instructions we have provided to you
for your distribution to beneficial owners. If the beneficial owner so
instructs, you should complete the appropriate subscription rights certificates
and submit them to the subscription agent with the proper payment. If you hold
shares of our common stock for the account(s) of more than one beneficial
owner, you may exercise the number of subscription rights to which all such
beneficial owners in the aggregate otherwise would have been entitled had they
been direct record holders of our common stock on the rights offering record
date, provided that you, as a nominee record holder, make a proper showing to
the subscription agent by submitting the form entitled "Nominee Holder
Certification" that we will provide to you with your rights offering materials.
If you did not receive this form, you should contact the subscription agent to
request a copy.
34
BENEFICIAL OWNERS
If you are a beneficial owner of shares of our common stock or will
receive your subscription rights through a broker, custodian bank or other
nominee, we will ask your broker, custodian bank or other nominee to notify you
of this rights offering. If you wish to exercise or sell your subscription
rights, you will need to have your broker, custodian bank or other nominee act
for you. If you hold certificates of our common stock directly and would prefer
to have your broker, custodian bank or other nominee act for you, you should
contact your nominee and request it to effect the transactions for you. To
indicate your decision with respect to your subscription rights, you should
complete and return to your broker, custodian bank or other nominee the form
entitled "Beneficial Owners Election Form." You should receive this form from
your broker, custodian bank or other nominee with the other rights offering
materials. If you wish to obtain a separate subscription rights certificate,
you should contact the nominee as soon as possible and request that a separate
subscription rights certificate be issued to you. You should contact your
broker, custodian bank or other nominee if you do not receive this form, but
you believe you are entitled to participate in this rights offering. We are not
responsible if you do not receive the form from your broker, custodian bank or
nominee or if you receive it without sufficient time to respond.
If you are a participant in our 401(k) plan, please refer to the
information set out in "--Special Instructions for Participants in Our 401(k)
Plan."
INSTRUCTIONS FOR COMPLETING YOUR SUBSCRIPTION RIGHTS CERTIFICATE
You should read and follow the instructions accompanying the subscription
rights certificates carefully.
You are responsible for the method of delivery of your subscription rights
certificate(s) with your subscription price payment to the subscription agent.
If you send your subscription rights certificate(s) and subscription price
payment by mail, we recommend that you send them by registered mail, properly
insured, with return receipt requested. You should allow a sufficient number of
days to ensure delivery to the subscription agent prior to the time this rights
offering expires. Because uncertified personal checks may take at least five
(5) business days to clear, you are strongly urged to pay, or arrange for
payment, by means of a certified or cashier's check, money order or wire
transfer of funds.
If you are a participant in our 401(k) plan, you will not receive a
subscription rights certificate, but you will be notified on a 401(k) Plan
Participant Election Form of the number of subscription rights that have been
allocated to you. Please refer to the information set out under "--Special
Instructions for Participants in Our 401(k) Plan."
DETERMINATIONS REGARDING THE EXERCISE OR SALE OF YOUR SUBSCRIPTION RIGHTS
We will decide all questions concerning the timeliness, validity, form and
eligibility of the exercise of your subscription rights and any such
determinations by us will be final and binding. We, in our sole discretion, may
waive, in any particular instance, any defect or irregularity, or permit, in
any particular instance, a defect or irregularity to be corrected within such
time as we may determine. We will not be required to make uniform
determinations in all cases. We may reject the exercise or sale of any of your
subscription rights because of any defect or irregularity. We will not accept
any exercise of subscription rights until all irregularities have been waived
by us or cured by you within such time as we decide, in our sole discretion.
Neither we, the subscription agent, the information agent nor the 401(k)
plan trustee, will be under any duty to notify you of any defect or
irregularity in connection with your submission of subscription rights
certificates and we will not be liable for failure to notify you of any defect
or irregularity. We reserve the right to reject your exercise of subscription
rights if your exercise is not in accordance with the terms of this rights
offering or in proper form. We will also not accept the exercise of your
subscription rights if our issuance of shares of our Class A common stock to
you could be deemed unlawful under applicable law.
35
SPECIAL INSTRUCTIONS FOR PARTICIPANTS IN OUR 401(K) PLAN
Our Class A common stock is one of the investments available under our
401(k) plan. Subscription rights will be allocated to 401(k) plan participants
for whose account the 401(k) plan holds shares of Class A comon stock on the
record date for this rights offering in proportion to the number of such shares
held on their behalf under the 401(k) plan as of that date. Those participants
will have the ability to direct the trustee of the 401(k) plan to sell or
exercise some or all of the subscription rights allocable to them. At ,
2003, the 401(k) plan was the record holder of shares of our Class A common
stock in the aggregate.
If shares of our Class A common stock are held by our 401(k) plan for your
account under our 401(k) plan as of the rights offering record date, you will
be notified by us of this rights offering and the number of subscription rights
that have been allocated to your account under our 401(k) plan. If you wish to
sell or exercise your subscription rights, in whole or in part, you will need
to notify the trustee of the 401(k) Plan of your decision and the trustee will
act for you. To indicate your decision, you should complete and return to the
trustee the form entitled "401(k) Plan Participant Election Form." You should
receive this form with the other rights offering materials. If you do not
receive this form, you should contact the information agent if you believe you
are entitled to participate in this rights offering with respect to shares you
hold under the 401(k) plan.
The trustee must receive your completed 401(k) Plan Participant Election
Form no later than 5:00 p.m., New York City time, on , 2003, seven days
prior to the expiration date of this rights offering, so that the trustee can
sell or exercise the subscription rights on your behalf prior to the expiration
date.
To the extent you elect to sell some or all of the subscription rights
allocated to you under the 401(k) plan, the trustee will attempt to sell those
rights on your behalf as soon as practicable after it receives the 401(k) Plan
Participant Election Form from you (provided that, to the extent that market
conditions prevent the sale of rights on any particular day, successive daily
attempts will be made to sell the rights until they are all sold). The
trustee's obligation to execute sell orders is subject to its ability to find
buyers for the subscription rights. We cannot assure you that a trading market
for the subscription rights can be maintained. Any direction to exercise your
rights will be implemented as described below. In any event, if you fail to
instruct the trustee to either sell or exercise your subscription rights on or
before , 2003, the trustee will attempt to sell the rights on your
behalf beginning on , 2003.
If you elect to exercise some or all of your subscription rights, you must
ensure that the total amount of the funds required for such exercise have been
allocated to an account created by you, or that you currently maintain, in the
Stable Value Fund (an existing investment election under the 401(k) plan) on
, 2003 in order to satisfy the subscription price payable by you upon
exercise of your subscription rights. On , 2003, the trustee, to
exercise subscription rights on your behalf in the rights offering, will
transfer such funds from your Stable Value Fund account to the subscription
agent. DO NOT SEND YOUR SUBSCRIPTION PRICE PAYMENT TO US, THE SUBSCRIPTION
AGENT OR THE INFORMATION AGENT. To the extent you do not already have
sufficient funds invested in a Stable Value Fund account to exercise the
subscription rights, you will need to liquidate a portion of your investments
in one or more of your other investment funds under the 401(k) plan and
transfer such funds into your existing or newly created Stable Value Fund
account by 2003, in an amount sufficient to exercise the subscription
rights in accordance with your election. If the amount that you have invested
in your Stable Value Fund account on , 2003 is insufficient to exercise
all of your subscription rights in accordance with your election, the
subscription rights will be exercised to the maximum extent possible with the
amount you have invested in the Stable Value Fund account, and, if an active
trading market for the rights is maintained, the trustee will attempt to sell
for your account any remaining rights that are not exercised because of
insufficient funds.
The net proceeds of any sale of rights (whether directed by you or
implemented by the trustee in the absence of direction or on account of
insufficient funds for exercise) will be allocated to your Stable Value Fund
account established under the 401(k) plan, where such funds will remain subject
to your further investment directions in accordance with the terms of the
401(k) plan. Any shares of our
36
Class A common stock purchased upon exercise of the subscription rights you
hold under the 401(k) plan will be allocated to the Employee Stock Fund
established under the 401(k) plan (which is the fund that holds newly--acquired
shares of our Class A common stock), where they will remain subject to your
further investment directions in accordance with the terms of the 401(k) plan.
Once you send to the trustee the form entitled "401(k) Plan Participant
Election Form," you may not revoke your exercise instructions. If you elect to
exercise your subscription rights, you should be aware that the market value of
our Class A common stock may go up or down during the period after you submit
your 401(k) Plan Participant Election Form to the trustee and before the time
that Class A common stock is purchased under the subscription rights and
allocated to your account under the 401(k) plan. See "Risk Factors--You may not
revoke your subscription exercise and could be committed to buying shares above
the prevailing market price." However, notwithstanding instructions from
participants of our 401(k) plan to exercise their subscription rights, the
trustee will not exercise the subscription rights if, on , 2003, the
per share public trading price of our Class A common stock is less than the per
share subscription price. The trustee may attempt, instead, to sell the
subscription rights; however, if the per share subscription price exceeds the
per share public trading price, it is likely that the subscription rights will
have no value. The trustee may also, from , 2003 through the expiration
of this rights offering, exercise the rights if the per share public trading
price increases above the per share subscription price.
If you terminate employment and request a distribution from the 401(k)
plan effective before the expiration of this rights offering, any subscription
rights allocated to your account at the time of distribution will be sold (to
the extent that a market is maintained) and any net sale proceeds will be
distributed to you in accordance with the otherwise applicable terms of the
401(k) plan.
Neither we, the subscription agent, the information agent nor the plan
trustee will be under any duty to notify you of any defect or irregularity in
connection with your submission of the 401(k) Plan Participant Election Form,
and we will not be liable for failure to notify you of any defect or
irregularity with respect to the completion of such form. We reserve the right
to reject your exercise or instructions for sale of subscription rights if your
exercise is, or instructions for sale are, not in accordance with the terms of
this rights offering or in proper form. We will also not accept the exercise of
your subscription rights if our issuance of shares of our Class A common stock
to you could be deemed unlawful under applicable law.
The 401(k) Plan Participant Election Form must be delivered to Putnam
Fiduciary Trust Company, the trustee of the 401(k) plan, at the address set
forth below:
By Mail:
PUTNAM INVESTMENTS
Defined Contribution Plan Administration
P.O. Box 9740
Providence, RI 02940-9889
By Hand Delivery or Overnight Courier:
PUTNAM INVESTMENTS
Investors Way
Norwood, MA 02062-9105
Delivery to any address or by a method other than those set forth above
does not constitute valid delivery.
REGULATORY LIMITATION
We will not be required to issue to you shares of our Class A common stock
pursuant to this rights offering if, in our opinion, you would be required to
obtain prior clearance or approval from any state or federal regulatory
authorities to own or control such shares if, at the time this rights offering
expires, you have not obtained such clearance or approval.
37
GUARANTEED DELIVERY PROCEDURES
If you wish to exercise your subscription rights, but you do not have
sufficient time to deliver the subscription rights certificate evidencing your
subscription rights to the subscription agent on or before the time this rights
offering expires, you may exercise your subscription rights by the following
guaranteed delivery procedures:
o Deliver to the subscription agent on or prior to the rights offering
expiration date your subscription price payment in full for each share
you subscribed for under your subscription privileges in the manner set
forth above in "--Method of Payment";
o Deliver to the subscription agent on or prior to the expiration date the
form entitled "Notice of Guaranteed Delivery," substantially in the form
provided with the "Instructions as to Use of Revlon, Inc. Subscription
Rights Certificates" distributed with your subscription rights
certificates; and
o Deliver the properly completed subscription rights certificate
evidencing your subscription rights being exercised and the related
nominee holder certification, if applicable, with any required signature
guarantee, to the subscription agent within three (3) New York Stock
Exchange trading days following the date of your Notice of Guaranteed
Delivery.
Your Notice of Guaranteed Delivery must be delivered in substantially the
same form provided with the Instructions as to the Use of Revlon, Inc.
Subscription Rights Certificates, which will be distributed to you with your
subscription rights certificate. Your Notice of Guaranteed Delivery must come
from an eligible institution, or other eligible guarantee institutions that are
members of, or participants in, a signature guarantee program acceptable to the
subscription agent.
In your Notice of Guaranteed Delivery, you must state:
o Your name;
o The number of subscription rights represented by your subscription
rights certificates, the number of shares of our Class A common stock
for which you are subscribing under your basic subscription privilege
and the number of shares of our Class A common stock for which you are
subscribing under your over-subscription privilege, if any; and
o Your guarantee that you will deliver to the subscription agent any
subscription rights certificates evidencing the subscription rights you
are exercising within three (3) business days following the date the
subscription agent receives your Notice of Guaranteed Delivery.
You may deliver your Notice of Guaranteed Delivery to the subscription
agent in the same manner as your subscription rights certificates at the
address set forth above under "--Delivery of Subscription Materials and
Payment." You may alternatively transmit your Notice of Guaranteed Delivery to
the subscription agent by facsimile transmission (Telecopy No.: (718)
234-5001). To confirm facsimile deliveries, you may call (718) 921-8200.
The information agent will send you additional copies of the form of
Notice of Guaranteed Delivery if you request them. Please call (800) 949-2583
to request any copies of the form of Notice of Guaranteed Delivery. Banks and
brokerage firms please call collect at (212) 269-5550 to request any copies of
the form of Notice of Guaranteed Delivery.
QUESTIONS ABOUT EXERCISING OR SELLING SUBSCRIPTION RIGHTS
If you have any questions or require assistance regarding the method of
exercising or selling your subscription rights or requests for additional
copies of this prospectus, the Instructions as to the Use of Revlon, Inc.
Subscription Rights Certificates or the Notice of Guaranteed Delivery, you
should contact the information agent at the address and telephone number set
forth above under "Summary--Questions and Answers About the Rights Offering"
included elsewhere in this prospectus.
38
SUBSCRIPTION AGENT AND INFORMATION AGENT
We have appointed American Stock Transfer & Trust Company to act as
subscription agent and D.F. King & Co., Inc. to act as information agent for
this rights offering. We will pay all fees and expenses of the subscription
agent and the information agent related to this rights offering and have also
agreed to indemnify the subscription agent and the information agent from
liabilities that they may incur in connection with this rights offering.
NO REVOCATION
Once you have exercised your subscription privileges, you may not revoke
your exercise. Subscription rights not exercised prior to the expiration date
of this rights offering will expire and will have no value.
PROCEDURES FOR DTC PARTICIPANTS
We expect that the exercise of your basic subscription privilege and your
over-subscription privilege may be made through the facilities of the
Depository Trust Company. If your subscription rights are held of record
through DTC, you may exercise your basic subscription privilege and your
over-subscription privilege by instructing DTC to transfer your subscription
rights from your account to the account of the subscription agent, together
with certification as to the aggregate number of subscription rights you are
exercising and the number of shares of our Class A common stock you are
subscribing for under your basic subscription privilege and your
over-subscription privilege, if any, and your subscription price payment for
each share of our Class A common stock that you subscribed for pursuant to your
basic subscription privilege and your over-subscription privilege.
SUBSCRIPTION PRICE
The subscription price is $ per share. For more information with
respect to how the subscription price was determined, see "Summary--Questions
and Answers About the Rights Offering" included elsewhere in this prospectus.
FOREIGN AND OTHER STOCKHOLDERS
We will not mail subscription rights certificates to stockholders on the
record date, or to subsequent transferees, whose addresses are outside the U.S.
Instead, we will have the subscription agent hold the subscription rights
certificates for those holders' accounts. To exercise their subscription
rights, foreign holders must notify the subscription agent before 11:00 a.m.,
New York City time, on , 2003, three business days prior to the
expiration date, and must establish to the satisfaction of the subscription
agent that it is permitted to exercise its subscription rights under applicable
law. If a foreign holder does not notify and provide acceptable instructions to
the subscription agent by such time (and if no contrary instructions have been
received), the subscription rights will be sold, subject to the subscription
agent's ability to find a purchaser. Any such sales will be deemed to be
effected at the weighted average sale price of all subscription rights sold by
the subscription agent on the relevant date of sale. See "--Method of
Transferring and Selling Subscription Rights." If the subscription agent sells
subscription rights for a foreign holder, the subscription agent will remit a
check for the proceeds from the sale of any subscription rights (less any
applicable commissions, taxes or broker fees) to such foreign holder by mail.
The proceeds, if any, resulting from sales of subscription rights pursuant to
the basic subscription privilege of holders whose addresses are not known by
the subscription agent or to whom delivery cannot be made will be held in an
interest bearing account. Any amount remaining unclaimed by foreign holders on
the second anniversary of the expiration date of this rights offering will be
remitted to us.
METHODS FOR TRANSFERRING AND SELLING SUBSCRIPTION RIGHTS
We anticipate that the subscription rights will be traded on the NYSE
under the symbol "REV RT." We expect that subscription rights may be purchased
or sold
39
until the close of business on the last trading day preceding the expiration
date. You may sell your subscription rights by contacting your broker or the
institution through which you hold your securities. In addition, if you are a
record holder of our common stock, you may sell your rights through the
subscription agent (as described below). However, there has been no prior public
market for the subscription rights, and we cannot assure you that a trading
market for the subscription rights will develop or, if a market develops, that
the market will remain available throughout the subscription period. We also
cannot assure you of the price at which the subscription rights will trade, if
at all. If you do not exercise or sell your subscription rights you will lose
any value inherent in the subscription rights. See "--General Considerations
Regarding the Partial Exercise, Transfer or Sale of Subscription Rights" below.
Transfer of Subscription Rights. You may transfer subscription rights in
whole by endorsing the subscription rights certificate for transfer. Please
follow the instructions for transfer included in the information sent to you
with your subscription rights certificate. If you wish to transfer only a
portion of the subscription rights, you should deliver your properly endorsed
subscription rights certificate to the subscription agent. With your
subscription rights certificate, you should include instructions to register
such portion of the subscription rights evidenced thereby in the name of the
transferee (and to issue a new subscription rights certificate to the
transferee evidencing such transferred subscription rights). You may only
transfer whole subscription rights and not fractions of a subscription right.
If there is sufficient time before the expiration of this rights offering, the
subscription agent will send you a new subscription rights certificate
evidencing the balance of your subscription rights that you did not transfer to
the transferee. You may also instruct the subscription agent to send the
subscription rights certificate to one or more additional transferees. If you
wish to sell your remaining subscription rights, you may request that the
subscription agent send you certificates representing your remaining (whole)
subscription rights so that you may sell them through your broker or dealer.
If you wish to transfer all or a portion of your subscription rights, you
should allow a sufficient amount of time prior to the time the subscription
rights expire for the subscription agent to:
o receive and process your transfer instructions; and
o issue and transmit a new subscription rights certificate to your
transferee or transferees with respect to transferred subscription
rights, and to you with respect to any subscription rights you retained.
If you wish to transfer your subscription rights to any person other than
a bank or broker, the signatures on your subscription rights certificate must
be guaranteed by an eligible institution.
If you are a participant in our 401(k) plan, please refer to the
information set out in "--Special Instructions for Participants in Our 401(k)
Plan."
Sales of Subscription Rights Through the Subscription Agent. If you are a
record holder of our Class A common stock and choose not to sell your
subscription rights through your broker or dealer, you may choose to sell your
subscription rights through the subscription agent. If you wish to have the
subscription agent seek to sell your subscription rights, you must deliver your
properly executed subscription rights certificate, with appropriate
instructions, to the subscription agent. If you want the subscription agent to
seek to sell only a portion of your subscription rights, you must send the
subscription agent instructions setting forth what you would like done with the
subscription rights along with your subscription rights certificate.
If the subscription agent sells subscription rights for you, it will send
you a check for the net proceeds from the sale of any of your subscription
rights, less any applicable commissions, taxes or broker fees, as soon as
practicable following the sale. If your subscription rights can be sold, the
sale will be deemed to have been made at the weighted average net sale price of
all subscription rights sold by the subscription agent on the relevant date of
sale. We cannot assure you, however, that a
40
market will develop for the purchase and sale of the subscription rights or
that the subscription agent will be able to sell your subscription rights.
You must deliver your order to sell your subscription rights to the
subscription agent before 11:00 a.m., New York City time, on _______, 2003, the
third business day before the expiration date. If less than all sales orders
received by the subscription agent are filled, it will prorate the sales
proceeds among you and the other subscription rights holders based upon the
number of subscription rights that each holder has instructed the subscription
agent to sell during that period, irrespective of when during the period the
instructions are received by it. The subscription agent is required to sell your
subscription rights only if it is able to find buyers.
IF YOU SELL YOUR SUBSCRIPTION RIGHTS THROUGH YOUR BROKER OR DEALER, YOU
MAY RECEIVE A DIFFERENT AMOUNT OF PROCEEDS THAN IF YOU SELL THE SAME AMOUNT OF
SUBSCRIPTION RIGHTS THROUGH THE SUBSCRIPTION AGENT. IF YOU SELL YOUR
SUBSCRIPTION RIGHTS THROUGH YOUR BROKER OR DEALER INSTEAD OF THE SUBSCRIPTION
AGENT, YOUR SALES PROCEEDS WILL BE THE ACTUAL SALES PRICE OF YOUR SUBSCRIPTION
RIGHTS LESS ANY APPLICABLE BROKERS COMMISSION, TAXES OR OTHER FEES, RATHER THAN
THE WEIGHTED AVERAGE NET SALE PRICE OF ALL SUBSCRIPTION RIGHTS SOLD BY THE
SUBSCRIPTION AGENT ON THE RELEVANT DATE DESCRIBED ABOVE.
If you are a participant in our 401(k) plan, please refer to the
information set out in "--Special Instructions for Participants in Our 401(k)
Plan."
General Considerations Regarding the Partial Exercise, Transfer or Sale of
Subscription Rights. The amount of time needed by your transferee to exercise
or sell its subscription rights depends upon the method by which you, as the
transferor, delivers the subscription rights certificates, the method of
payment made by your transferee and the number of transactions that the holder
instructs the subscription agent to effect. You should also allow up to ten
business days for your transferee to exercise or sell the subscription rights
that you transferred to it. Neither we nor the subscription agent will be
liable to a transferee or transferor of subscription rights if subscription
rights certificates or any other required documents are not received in time
for exercise or sale prior to the expiration time.
You will receive a new subscription rights certificate upon a partial
exercise, transfer or sale of subscription rights only if the subscription
agent receives your properly endorsed subscription rights certificate no later
than 5:00 p.m., New York City time, three business days before the expiration
date. The subscription agent will not issue a new subscription rights
certificate if your subscription rights certificate is received after that time
and date. If your instructions and subscription rights certificate are received
by the subscription agent after that time and date, you will not receive a new
subscription rights certificate and therefore will not be able to sell or
exercise your remaining subscription rights.
You are responsible for all commissions, fees and other expenses
(including brokerage commissions and transfer taxes) incurred in connection
with the purchase, sale or exercise of your subscription rights, except that we
will pay any fees of the subscription agent and information agent associated
with this rights offering. Any amounts you owe will be deducted from your
account.
If you do not exercise or sell your subscription rights before the
expiration date, your subscription rights will expire without value and will no
longer be exercisable.
CANCELLATION RIGHTS
Our board of directors may cancel this rights offering, in whole or in
part, in its sole discretion at any time prior to the time this rights offering
expires for any reason (including a change in the market price of our Class A
common stock). If we cancel this rights offering, any funds you paid to the
subscription agent will be promptly refunded, without interest or deduction.
NO BOARD OR SPECIAL COMMITTEE RECOMMENDATION
An investment in shares of our Class A common stock must be made according
to each investor's evaluation of its own best interests and after considering
all of the information in this prospectus, including the "Risk Factors" section
of this prospectus and all of the information incorporated by
41
reference in this prospectus. Neither we, our board of directors nor the
special committee of our board of directors makes any recommendation to
subscription rights holders regarding whether they should exercise or sell
their subscription rights. You should not view MacAndrews & Forbes' agreements
under the Investment Agreement as a recommendation or other indication by
MacAndrews & Forbes or our board of directors that the exercise of your
subscription rights is in your best interests.
SHARES OF COMMON STOCK OUTSTANDING AFTER THE RIGHTS OFFERING
Based on the 20,516,135 shares of our Class A common stock issued and
outstanding as of , 2003, approximately 42,255,265 shares of our Class A
common stock will be issued and outstanding after this rights offering expires,
an increase in the number of outstanding shares of our Class A common stock of
approximately 106%. The 31,250,000 shares of our Class B common stock, all of
which are beneficially owned by MacAndrews & Forbes as of , 2003,
will remain outstanding.
EFFECTS OF RIGHTS OFFERING ON STOCK PLAN AND OTHER PLANS
As of December 31, 2002, there were outstanding 2,005,000 restricted
shares and options to purchase 7,886,064 shares of our Class A common stock
issued or committed to be issued pursuant to stock options granted by us and
our affiliates. None of the outstanding options or restricted shares have
antidilution or other provisions of adjustment that will be triggered by this
rights offering. Each outstanding and unexercised option will remain unchanged
and will be exercisable, subject to vesting, if any, for the same number of
shares of our Class A common stock and at the same exercise price as before
this rights offering. Similarly, each restricted share will remain unchanged.
EFFECTS OF RIGHTS OFFERING ON THE MACANDREWS & FORBES' SECURITIES AND OWNERSHIP
Even though the subscription rights will be offered on a pro rata basis to
each holder of our Class A and Class B common stock, because of MacAndrews &
Forbes' commitment to back-stop this rights offering, the percentage of common
stock owned by other stockholders will decrease unless all of the other
stockholders exercise the subscription rights they will receive in full.
Set forth below, for illustrative purposes only, are two scenarios that
indicate the effect that this rights offering and related share issuance could
have on MacAndrews & Forbes' relative voting and economic interest. As of the
date of this prospectus, MacAndrews & Forbes controls approximately 97% of the
voting power of our outstanding capital stock and owns approximately 83% of our
outstanding common stock.
SCENARIO A -- All subscription rights are subscribed for on a pro rata
basis by all of the stockholders to whom the subscription rights were issued,
except MacAndrews & Forbes, and MacAndrews & Forbes purchases the full number
of shares of our Class A common stock it would have been entitled to subscribe
for in this rights offering in accordance with its basic subscription
privilege. Because all of the subscription rights are exercised in the basic
subscription privilege by holders other than MacAndrews & Forbes and MacAndrews
& Forbes purchases the number of shares equivalent to its full pro rata portion
of the shares offered pursuant to the basic subscription privilege to which it
would otherwise have been entitled, no shares are exercisable in the
over-subscription privilege and MacAndrews & Forbes does not need to back-stop
this rights offering.
SCENARIO B -- MacAndrews & Forbes is the only stockholder to acquire
shares of our Class A common stock, which number of shares is equivalent to the
full number of shares of our Class A common stock it would have been entitled
to subscribe for in this rights offering in accordance with its basic
subscription privilege and, through the back-stop, MacAndrews & Forbes acquires
all of the shares offered in this rights offering.
42
NO. OF SHARES
PURCHASED BY MACANDREWS
TOTAL SHARES MACANDREWS & FORBES MACANDREWS & FORBES
SCENARIO OFFERED & FORBES CASH RAISED VOTING % ECONOMIC OWNERSHIP PERCENTAGE
---------- -------------- -------------- ------------- ----------- -------------------------------
AT MAXIMUM
UNDILUTED (a) DILUTION (b)
--------------- -------------
A 21,739,130 18,021,739 $50,000,000 97% 83% 83%
B 21,739,130 21,739,130 $50,000,000 98% 88% 88%
(a) Does not give effect to conversion of our Series B convertible preferred
stock and includes Class B common stock.
(b) Assumes conversion in full of the Series B convertible preferred stock and
includes Class B common stock.
OTHER MATTERS
We are not making this rights offering in any state or other jurisdiction
in which it is unlawful to do so, nor are we distributing or accepting any
offers to purchase any shares of our Class A common stock from subscription
rights holders who are residents of those states or other jurisdictions or who
are otherwise prohibited by federal or state laws or regulations to accept or
exercise the subscription rights. We may delay the commencement of this rights
offering in those states or other jurisdictions, or change the terms of this
rights offering, in whole or in part, in order to comply with the securities
law or other legal requirements of those states or other jurisdictions. We may
decline to make modifications to the terms of this rights offering requested by
those states or other jurisdictions, in which case, if you are a resident in
those states or jurisdictions or if you are otherwise prohibited by federal or
state laws or regulations from accepting or exercising the subscription rights
you will not be eligible to participate in this rights offering.
INVESTMENT AGREEMENT
Pursuant to an Investment Agreement between Revlon, Products Corporation
and MacAndrews Holdings, dated February 5, 2003, among other things, MacAndrews
& Forbes agreed:
o to purchase in a private placement the full number of shares of our
Class A common stock it would otherwise have been entitled to subscribe
for in this rights offering in accordance with its basic subscription
privilege;
o to not exercise the over-subscription privilege that it would otherwise
be entitled to exercise in this rights offering;
o to back-stop this rights offering by purchasing in a private placement
all of the shares of our Class A common stock that are not otherwise
subscribed for by the other holders of subscription rights under their
basic subscription privileges and over-subscription privileges; and
o to make available to us (i) the $50 million Series C preferred stock
investment, if any, which shares would be redeemed upon consummation of
this rights offering, (ii) the MacAndrews & Forbes $100 million term
loan and (iii) the $40-65 million line of credit.
The Investment Agreement also provides that, in lieu of paying cash to
satisfy its obligations referred to in the first and third bullet points above,
at the consummation of the rights offering, MacAndrews & Forbes may elect to
satisfy all or part of such obligations by offsetting such obligations against
MacAndrews & Forbes' right to receive from us the cash redemption proceeds with
respect to the Series C preferred stock then held by MacAndrews & Forbes, if
any. In addition, the Investment Agreement provides that any shares of our
Class A common stock acquired by MacAndrews & Forbes in transactions
contemplated by the Investment Agreement will be deemed to be registrable
securities under the existing registration rights agreement between us and REV
Holdings LLC.
43
DESCRIPTION OF CAPITAL STOCK
We are authorized to issue two classes of common stock, Class A common
stock and Class B common stock, the two classes of which are substantially
identical, except as to their voting power. We are authorized to issue
350,000,000 shares of Class A common stock, 20,516,135 of which were
outstanding as of December 31, 2002, and 200,000,000 shares of Class B common
stock, 31,250,000 of which were outstanding as of December 31, 2002. We are
also authorized to issue 20,000,000 shares of preferred stock, of which we have
two series, Series A preferred stock and Series B convertible preferred stock.
We had 546 shares of Series A preferred stock and 4,333 shares of Series B
convertible preferred stock outstanding as of December 31, 2002, all of which
were owned by REV Holdings.
The following summary description of our capital stock is based on our
Amended and Restated Certificate of Incorporation (referred to in this
prospectus as the Certificate of Incorporation) and our Amended and Restated
By-laws (referred to in this prospectus as the By-laws).
CLASS A COMMON STOCK AND CLASS B COMMON STOCK
Each share of our Class A common stock entitles the holder to one vote and
each share of our Class B common stock entitles the holder to ten votes at each
annual or special meeting of stockholders, in the case of any written consent
of stockholders and for all other purposes on all matters being voted on by our
stockholders. The holders of our Class A common stock and our Class B common
stock vote as a single class on all matters submitted to a vote of our
stockholders, except as otherwise provided by law. Neither the holders of our
Class A common stock nor the holders of our Class B common stock have
cumulative voting or preemptive rights.
The holders of our Class A common stock and our Class B common stock are
entitled to receive dividends and other distributions as may be declared by our
board of directors out of assets or funds legally available for that purpose,
subject to the rights of the holders of any series of our preferred stock, and
any other provision of our Certificate of Incorporation. Our Certificate of
Incorporation provides that if at any time a dividend or other distribution in
cash or other property is paid on our Class A common stock or our Class B
common stock, a like dividend or other distribution in cash or other property
will also be paid on our Class B common stock or our Class A common stock, as
the case may be, in an equal amount per share. Our Certificate of Incorporation
provides that if shares of our Class A common stock are paid on our Class A
common stock and shares of our Class B common stock are paid on our Class B
common stock in an equal amount per share of our Class A common stock and our
Class B common stock, such payment will be deemed to be a like dividend or
other distribution. We did not declare or pay dividends during 2002 or 2001.
We, as a holding company, will be dependent on the earnings and cash flow of,
and dividends and distributions from, Products Corporation to pay our expenses
and to pay any cash dividend or distribution on our Class A common stock that
may be authorized by our board of directors. See "Risk Factors--We are a
holding company with no business operations of our own and are dependent on our
subsidiaries to pay certain expenses and dividends." In the case of any split,
subdivision, combination or reclassification of our Class A common stock or our
Class B common stock, the shares of our Class B common stock or our Class A
common stock, as the case may be, will also be split, subdivided, combined or
reclassified so that the number of shares of our Class A common stock and our
Class B common stock outstanding immediately following such split, subdivision,
combination or reclassification will bear the same relationship to each other
as that which existed immediately prior to the split, subdivision, combination
or reclassification.
In the event of our liquidation, dissolution or winding up, the holders of
our Class A common stock and the holders of our Class B common stock will be
entitled to receive assets and funds available for distribution after payments
to creditors and to the holders of any of our preferred stock that may at the
time be outstanding, in proportion to the number of shares held by them,
respectively, without regard to class.
In the event of any corporate merger, consolidation, purchase or
acquisition of property or stock, or other reorganization in which any
consideration is to be received by the holders of our Class A
44
common stock or the holders of our Class B common stock, the holders of our
Class A common stock and the holders of our Class B common stock will receive
the same consideration on a per share basis. However, if such consideration
consists of any voting securities (or of options or warrants to purchase, or of
securities convertible into or exchangeable for, voting securities), the
holders of our Class B common stock may receive, on a per share basis, voting
securities with ten times the number of votes per share as those voting
securities to be received by the holders of our Class A common stock (or
options or warrants to purchase, or securities convertible into or exchangeable
for, voting securities with ten times the number of votes per share as those
voting securities issuable upon exercise of the options or warrants, or into
which the convertible or exchangeable securities to be received by the holders
of our Class A common stock may be converted or exchanged).
Our Certificate of Incorporation provides that no person holding record or
beneficial ownership of shares of our Class B common stock (referred to in this
prospectus as a Class B Holder) may transfer, and we will not register the
transfer of, such shares of our Class B common stock, except to a permitted
transferee. A permitted transferee is generally defined to mean an affiliate of
the Class B Holder. In certain circumstances set forth in our Certificate of
Incorporation, changes in ownership or control of a Class B Holder will also
result in the conversion of such holder's Class B common stock into our Class A
common stock. Our Certificate of Incorporation also provides that we will not
register the transfer of any shares of our Class B common stock unless the
transferee and the transferor of such Class B common stock have furnished such
affidavits and other proof as we reasonably may request to establish that the
proposed transferee is a permitted transferee. In addition, upon any purported
transfer of shares of our Class B common stock not permitted under our
Certificate of Incorporation, all shares of our Class B common stock purported
to be transferred will be deemed to be converted into shares of our Class A
common stock, and stock certificates formerly representing such shares of our
Class B common stock will from that time be deemed to represent the number of
shares of our Class A common stock as equals the number of shares of our Class
A common stock into which such shares of our Class B common stock could be
converted pursuant to the Certificate of Incorporation.
In the event that the number of shares of our Class B common stock and
Class A common stock held by the Class B Holders and their permitted
transferees issued and outstanding at any time shall constitute less than ten
percent of the total combined number of shares of our Class A common stock and
Class B common stock issued and outstanding at such time, then, without further
action on the part of the Class B Holder or us, all shares of our Class B
common stock then issued and outstanding will be deemed to be converted into
shares of our Class A common stock, and stock certificates formerly
representing such shares of our Class B common stock will from that time be
deemed to represent such number of shares of our Class A common stock as equals
the number of shares of our Class A common stock into which such shares of our
Class B common stock could be converted pursuant to our Certificate of
Incorporation. In addition, each share of our Class B common stock shall be
convertible, at the option of its record holder, into one validly issued, fully
paid and non-assessable share of our Class A common stock at any time.
Except as expressly set forth in our Certificate of Incorporation, the
rights of the holders of our Class A common stock and the rights of the Class B
Holders are in all respects identical.
Our Class A common stock is traded on the NYSE under the symbol "REV."
SERIES A PREFERRED STOCK AND SERIES B CONVERTIBLE PREFERRED STOCK
Our Certificate of Incorporation provides that we may issue shares of
preferred stock from time to time in one or more series. Our board of directors
is authorized to fix the voting rights, if any, designations, powers,
preferences and the relative participation, optional or other rights, if any,
and the qualifications, limitations or restrictions thereof, of any unissued
series of preferred stock, to fix the number of shares constituting such
series, and to increase or decrease the number of shares of any such series
(but not below the number of shares of such series then outstanding).
The holder of our Series A preferred stock is not entitled to receive any
dividends. Our Series A preferred stock is entitled to a liquidation preference
of $100,000 per share before any distribution is
45
made to the holders of our Class A or Class B common stock. The holder of our
Series A preferred stock does not have any voting rights, except as required by
law. Our Series A preferred stock may be redeemed at any time by us, at our
option, for $100,000 per share. However, the terms of Product Corporation's
existing bank credit agreement, the indentures covering its outstanding
indebtedness, the MacAndrews & Forbes $100 million term loan and the $40-65
million line of credit currently restrict our ability to effect such redemption
by limiting the amount of dividends or distributions Products Corporation can
pay to us.
The holder of our Series B convertible preferred stock is entitled to
receive dividends in an amount per share equal to the amount received by each
share of our Class A common stock as if our Series B convertible preferred
stock had been converted into shares of our Class A common stock as of the date
immediately prior to the record date for such dividend or distribution. No
dividend may be paid or declared on any share of our Class A common stock
unless a dividend, payable in the same consideration and manner, is
simultaneously paid or declared on each share of our Series B convertible
preferred stock.
Our Series B convertible preferred stock is entitled to a liquidation
preference of $720.0554 per share plus the amount of any declared but unpaid
dividends as of the date of liquidation before any distribution is made to the
holders of any of our Class A or Class B common stock or any other class or
series of our capital stock ranking junior as to liquidation rights to our
Series B convertible preferred stock. If, upon liquidation, our available
assets are insufficient to permit payment of the full liquidation preference to
the holders of our Series B convertible preferred stock, all of our available
assets shall be distributed among the holders of the then outstanding shares of
our Series B convertible preferred stock and the then outstanding shares of
capital stock ranking on parity with our Series B convertible preferred stock
as to distributions upon liquidation, pro rata according to the number of the
then outstanding shares of our Series B convertible preferred stock and the
then outstanding shares of such parity stock held by each such holder.
In addition to such rights as specified in our Certificate of
Incorporation and as are provided under Delaware law, the holder of our Series
B convertible preferred stock is entitled to vote together with the holders of
our Class A and Class B common stock as a single class at each annual or
special meeting of stockholders, in the case of any written consent of
stockholders and for all other purposes on all matters being voted on by the
stockholders. Each share of our Series B convertible preferred stock entitles
its holder to cast one vote for each whole vote that such holder would be
entitled to cast had such holder converted its Series B convertible preferred
stock into shares of our Class A common stock as of the date immediately prior
to the record date for determining the stockholders eligible to vote on any
such matter. In addition, we cannot, without the written consent or affirmative
vote of the holders of at least a majority of the outstanding shares of our
Series B convertible preferred stock voting separately as one class: (i) amend,
alter or repeal our Certificate of Incorporation or our By-laws if such
amendment, alteration or repeal would adversely alter or change the rights,
preferences or privileges of our Series B convertible preferred stock, (ii)
create or authorize any class, series or shares of preferred stock or any other
class or series of capital stock or other equity securities ranking either as
to payment of dividends or distribution of assets upon liquidation prior to our
Series B convertible preferred stock or on a parity with our Series B
convertible preferred stock, (iii) undertake any action, the valid consummation
of which would require the approval of our stockholders pursuant to our
Certificate of Incorporation or our By-laws or as required by applicable law
and the direct or indirect result of which would adversely affect or change the
rights, preferences or privileges of our Series B convertible preferred stock.
The holder of our Series B convertible preferred stock is entitled to
convert each of its shares of our Series B convertible preferred stock into a
number of shares of our Class A common stock determined by dividing the
liquidation preference of such shares by the conversion price, which is
initially $7.20 but is subject to adjustment upon stock dividends, subdivisions,
split ups or combinations, and to receive payment in lieu of any fractional
shares that would otherwise be due upon conversion. Each share of our Series B
convertible preferred stock is currently convertible into 100 shares of our
Class A common stock. In the event of any capital reorganization,
reclassification of our capital stock, or consolidation or merger with or into
another corporation (where we are not the
46
surviving corporation or where there is a change in or distribution with
respect to the common stock), each share of our Series B convertible preferred
stock shall after such event be convertible into the kind and number of shares
or other securities or property of us or of the successor corporation resulting
from such consolidation or surviving such merger, if any, to which the holder
of the number of shares of our Class A common stock deliverable upon conversion
of such Series B convertible preferred stock (had such conversion taken place
immediately prior to the time of such reorganization, reclassification,
consolidation or merger) would have been entitled to receive upon such
reorganization, reclassification, consolidation or merger.
We have the option to redeem all or any part of our Series B convertible
preferred stock at any time after 30 days following the requisite stockholder
approval at a redemption price equal to $720.0554 per share plus the amount of
any declared but unpaid dividends thereon as of such redemption date, provided
that the holders of our Series B convertible preferred stock retain the right
to convert their shares of our Series B convertible preferred stock into the
applicable number of shares of our Class A common stock until the close of
business on the last business day preceding the effective date of any such
optional redemption by us.
SECTION 203 OF THE DELAWARE GENERAL CORPORATION LAW
Section 203 of the General Corporation Law of the State of Delaware
provides, in general, that a stockholder acquiring more than 15% of the
outstanding voting stock of a corporation subject to the statute (referred to
in this prospectus as an Interested Stockholder) but less than 85% of such
stock may not engage in certain business combinations (as defined in Section
203) with the corporation for a period of three years subsequent to the date on
which the stockholder became an Interested Stockholder unless (i) prior to such
time the corporation's board of directors approved either the business
combination or the transaction in which the stockholder became an Interested
Stockholder or (ii) the business combination is approved by the corporation's
board of directors and authorized by a vote of at least 66 2/3% of the
outstanding voting stock of the corporation not owned by the Interested
Stockholder. Our Certificate of Incorporation contains a provision electing not
to be governed by Section 203.
USE OF PROCEEDS
Our gross proceeds from this rights offering will be $50 million, which
will include proceeds from the purchase in a private placement by MacAndrews &
Forbes of the number of shares of our Class A common stock it would otherwise
have been entitled to subscribe for in this rights offering and could include
proceeds from MacAndrews & Forbes pursuant to its arrangement to back-stop this
rights offering. The net proceeds from this rights offering, combined with the
proceeds from the MacAndrews & Forbes $100 million term loan as well as the
$40-65 million line of credit, if any, will be used for general corporate
purposes, including to help fund a portion of the costs and expenses of the
stabilization and growth phase of our plan, which includes increasing
advertising and media spending and effectiveness, increasing the marketing
effectiveness of our wall displays, including by streamlining the number of our
SKUs, selectively adjusting prices on certain products, optimizing product
availability to consumers, further strengthening our new product development
process, and for other general corporate purposes. Alternatively, the net
proceeds from this rights offering will be used to fund the costs of redeeming
the $50 million Series C preferred stock investment, if any. Assuming that this
rights offering is consummated in the second quarter of 2003, we do not
currently anticipate that we will require that MacAndrews & Forbes make the $50
million Series C preferred stock investment.
However, if we require MacAndrews & Forbes to make the $50 million Series
C preferred stock investment, our Series C preferred stock, when issued, would
be non-voting, non-dividend paying, non-convertible stock which would, with
respect to rights to distributions upon the liquidation, winding-up or
dissolution of us, rank senior to all classes of our common stock, pari passu
with our Series A preferred stock and junior to our Series B preferred stock.
The Series C preferred stock would be optionally redeemable by us upon
satisfaction of certain conditions at any time at a cash
47
redemption price equivalent to the face amount of the stock. In addition, the
Series C preferred stock would be redeemable on a mandatory basis by us in the
event that this rights offering is consummated.
DILUTION
Purchasers of our Class A common stock in this rights offering will
experience an immediate dilution of the net tangible book value per share of
our Class A common stock. Our net tangible book value as of December 31, 2002
was approximately $(1,863.0) million, or $(35.99) per share of our Class A and
Class B common stock. Net tangible book value per share is equal to our total
net tangible book value, which is our total tangible assets less our total
liabilities, divided by the number of shares of our outstanding Class A and
Class B common stock. Dilution per share equals the difference between the
amount per share paid by purchasers of shares of Class A common stock in this
rights offering and the net tangible book value per share of our Class A and
Class B common stock immediately after this rights offering. Based on an
assumed subscription price of $2.30 per share (which represents 80% of the
closing price per share of our Class A common stock on the NYSE on January 30,
2003, the trading day before the date that our board of directors approved this
rights offering) and after deducting estimated offering expenses payable by us,
and the application of the estimated net proceeds from this rights offering,
our pro forma net tangible book value as of December 31, 2002 would have been
approximately $(1,815.6) million, or $(24.70) per share. This represents an
immediate increase in pro forma net tangible book value to existing stockholders
of $11.29 per share and an immediate dilution to purchasers in this rights
offering of $27.00 per share. The following table illustrates this per share
dilution:
Subscription price ............................................................... $ 2.30
Net tangible book value per share prior to this rights offering ................. $ (35.99)
Increase per share attributable to this rights offering ......................... 11.29
Pro forma net tangible book value per share after this rights offering ........... (24.70)
--------
Dilution in net tangible book value per share to purchasers ...................... $ 27.00
========
If the subscription price were $2.45 per share, which represents 80% of
the highest closing price per share or our Class A common stock on the NYSE in
the 30-day period prior to April 25, 2003, our pro forma net tangible book
value as of December 31, 2002 would have been approximately $(1,815.6) million,
or $(25.16) per share. This would represent an immediate increase in pro forma
net tangible book value to existing stockholders of $10.83 per share and an
immediate dilution to purchasers in this rights offering of $27.61 per share.
48
CAPITALIZATION
The following table sets forth our capitalization as of December 31, 2002,
as adjusted to give pro forma effect to this rights offering and the MacAndrews
& Forbes $100 million term loan as if such transactions had occurred on December
31, 2002. The table should be read in conjunction with "Unaudited Pro Forma
Consolidated Financial Data" and with our consolidated financial statements and
the notes to those financial statements included in the documents incorporated
by reference in this prospectus.
AS OF DECEMBER 31, 2002
---------------------------------
ACTUAL AS ADJUSTED
------------ ------------------
(DOLLARS IN MILLIONS,
EXCEPT PER SHARE DATA)
Short-term borrowings ........................................................ $ 25.0 $ 25.0
Long-term debt:
Credit agreement ............................................................ 223.1 223.1
Term loan (a) ............................................................... -- 100.0
12% Senior Secured Notes due 2005 ........................................... 353.3 353.3
8 1/8% Senior Notes due 2006 ................................................ 249.7 249.7
9% Senior Notes due 2006 .................................................... 250.0 250.0
8 5/8% Senior Subordinated Notes due 2008 ................................... 649.9 649.9
Advances from Holdings ...................................................... 24.1 24.1
---------- -----------
Total indebtedness ........................................................... 1,775.1 1,875.1
---------- -----------
Stockholders' deficiency:
Preferred stock, par value $0.01 per share, 20,000,000 shares authorized,
546 shares of Series A Preferred Stock are issued and outstanding ......... 54.6 54.6
Preferred stock, par value $0.01 per share, 20,000,000 shares authorized,
4,333 shares of Series B Convertible Preferred Stock issued and
outstanding ............................................................... -- --
Class B Common Stock, par value $0.01 per share, 200,000,000 shares
authorized, 31,250,000 shares are issued and outstanding .................. 0.3 0.3
Class A Common Stock, par value $0.01 per share, 350,000,000 shares
authorized, 20,516,135 shares are issued and outstanding and
42,255,265 pro forma issued and outstanding (b) ........................... 0.2 0.4
Capital deficiency .......................................................... (201.3) (154.1)(c)
Accumulated deficit since June 24, 1992 ..................................... (1,361.9) (1,361.9)(c)
Accumulated other comprehensive loss ........................................ (132.7) (132.7)(c)
---------- -----------
Total stockholders' deficiency ............................................... (1,640.8) (1,593.4)(c)
---------- -----------
Total capitalization ......................................................... $ 134.3 $ 281.7(c)
========== ===========
(a) Assumes total commitment under the MacAndrews & Forbes $100 million term
loan is outstanding and excludes funds available under the $40-65 million
line of credit.
(b) Assumes 21,739,130 shares of common stock are issued pursuant to this
rights offering and the private placement of shares to MacAndrews & Forbes
at an assumed subscription price of $2.30 per share (which represents 80%
of the closing price per share of our Class A common stock on the NYSE on
January 30, 2003, the trading day before the date that our board of
directors approved this rights offering).
(c) If the subscription price on the record date of this rights offering were
$2.45, which represents 80% of the highest closing price per share of our
Class A common stock on the NYSE in the 30-day period prior to April
25, 2003, and an assumed 20,408,163 shares of common stock are issued
pursuant to this rights offering and the private placement of shares to
MacAndrews & Forbes, the pro forma value of Class A common stock would be
$0.40, the pro forma capital deficiency would be $154.1, the pro forma
total stockholders' deficiency would be $1,593.4 million and the pro forma
total capitalization would be $281.7 million.
49
UNITED STATES FEDERAL INCOME TAX CONSEQUENCES
The following discussion sets forth the opinion of our counsel, Skadden,
Arps, Slate, Meagher & Flom LLP, regarding the material federal income tax
consequences of this rights offering to holders of our common stock that hold
such stock as a capital asset for federal income tax purposes. This discussion
is based on laws, regulations, rulings and decisions in effect on the date
hereof, all of which are subject to change (possibly with retroactive effect)
and to differing interpretations. This discussion applies only to holders that
are U.S. persons and does not address all aspects of federal income taxation
that may be relevant to holders in light of their particular circumstances or to
holders who may be subject to special tax treatment under the Internal Revenue
Code, including, without limitation, holders of preferred stock or warrants,
holders who are dealers in securities or foreign currency, foreign persons,
insurance companies, tax-exempt organizations, banks, financial institutions,
broker-dealers, holders who hold common stock as part of a hedge, straddle,
conversion or other risk reduction transaction, or who acquired common stock
pursuant to the exercise of compensatory stock options or otherwise as
compensation.
We have not sought, and will not seek, a ruling from the Internal Revenue
Service regarding the federal income tax consequences of this rights offering
or the related share issuance. The following discussion does not address the
tax consequences of this rights offering or the related share issuance under
foreign, state, or local tax laws. ACCORDINGLY, EACH HOLDER OF COMMON STOCK
SHOULD CONSULT ITS TAX ADVISOR WITH RESPECT TO THE PARTICULAR TAX CONSEQUENCES
OF THIS RIGHTS OFFERING OR THE RELATED SHARE ISSUANCE TO SUCH HOLDER.
For U.S. federal income tax purposes, neither the receipt nor the exercise
of the subscription rights will result in taxable income to you. Moreover, you
will not realize a loss if you do not exercise the subscription rights. The
holding period for a share acquired upon exercise of a subscription right
begins with the date of exercise. The basis for determining gain or loss upon
the sale of a share acquired upon the exercise of a subscription right will be
equal to the sum of:
o the subscription price per share;
o any servicing fee charged to you by your broker, bank or trust company;
and
o the basis, if any, in the subscription rights that you exercised.
A gain or loss recognized upon a sale of a share acquired upon the
exercise of a subscription right will be a capital gain or loss assuming the
share is held as a capital asset at the time of sale. This gain or loss will be
a long-term capital gain or loss if the share has been held at the time of sale
for more than one year.
As noted above, your basis in a share issued under the subscription rights
offer includes your basis in the subscription rights underlying that share. If
the aggregate fair market value of the subscription rights at the time they are
distributed is less than 15% of the aggregate fair market value of our common
stock at such time, the basis of the subscription rights issued to you will be
zero unless you elect to allocate a portion of your basis of previously owned
common stock to the subscription rights issued to you in this rights offering.
If the aggregate fair market value of the subscription rights at the time they
are distributed is 15% or more of the aggregate fair market value of our common
stock at such time, or if you elect to allocate a portion of your basis of
previously owned common stock to the subscription rights issued to you in this
offering, then your basis in previously owned common stock will be allocated
between such common stock and the subscription rights based upon the relative
fair market value of such common stock and the subscription rights as of the
date of the distribution of the subscription rights. Thus, if such an
allocation is made and the rights are later exercised, the basis in the common
stock you originally owned will be reduced by an amount equal to the basis
allocated to the subscription rights. An election must be made in a statement
attached to your federal income tax return for the year in which the
subscription rights are distributed. If the subscription rights expire without
exercise, you will realize no loss and no portion of your basis in the common
stock will be allocated to the unexercised subscription rights.
If you sell, exchange or otherwise dispose of subscription rights received
in the rights offering prior to the expiration date, you will recognize capital
gain or loss equal to the difference between (i)
50
the amount of cash and the fair market value of any property received, and (ii)
your tax basis (if any) in the subscription rights disposed of. Any such
capital gain or loss will be long-term capital gain or loss if your holding
period for the subscription rights exceeds one year at the time of disposition.
Your holding period for the subscription rights received in the rights offering
will include your holding period for the common stock with respect to which the
rights were received.
LEGAL MATTERS
The validity and binding effect of the subscription rights and the
validity of the shares of Class A common stock offered pursuant to this rights
offering will be passed upon for us by Robert K. Kretzman, Esq., Senior Vice
President, General Counsel and Secretary of Revlon. Mr. Kretzman holds
restricted shares of our Class A common stock and options to acquire shares of
our Class A common stock and has an interest in shares of our Class A common
stock held by our 401(k) plan. Skadden, Arps, Slate, Meagher & Flom LLP, New
York, New York, has advised us as to certain tax matters related to this rights
offering. Skadden, Arps, Slate, Meagher & Flom LLP has from time to time
represented, and may continue to represent, MacAndrews & Forbes and certain of
its affiliates (including us) in connection with certain legal matters.
EXPERTS
Our consolidated financial statements and the related financial statement
schedule incorporated in this prospectus by reference from our Annual Report on
Form 10-K for the year ended December 31, 2002 have been audited by KPMG LLP,
independent certified public accountants, as stated in their report, which is
incorporated herein by reference, and have been so incorporated in reliance
upon the report of such firm given upon their authority as experts in
accounting and auditing.
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
The SEC allows us to "incorporate by reference" information that we file
with them, which means that we can disclose important information to you by
referring you to those documents. Specifically, we are incorporating by
reference the following documents listed below:
o Our Annual Report on Form 10-K for the year ended December 31, 2002,
filed on March 21, 2003; and
o Our Current Report on Form 8-K dated and filed on February 5, 2003.
A copy of our Annual Report on Form 10-K for the fiscal year ended
December 31, 2002 is included with this prospectus. You may request a copy, at
no cost, by writing or telephoning us at the following address:
Robert K. Kretzman, Esq.
Senior Vice President,
General Counsel and Secretary
Revlon, Inc.
625 Madison Avenue
New York, NY 10022
Telephone: (212) 527-4000
This prospectus is part of a registration statement we filed with the SEC.
You should rely only on the information provided in this prospectus or
incorporated by reference. We have not authorized anyone else to provide you
with different information. You should not assume that the information in this
prospectus is accurate as of any date other than the date on the front of the
document. We are not making an offer of these securities in any state where the
offer is not permitted.
Any statement contained in this prospectus or in a document, all or a
portion of which is incorporated or deemed to be incorporated by reference in
this prospectus, shall be deemed to be modified or superseded for purposes of
this prospectus to the extent that a statement contained in this prospectus or
in any other subsequently filed document that also is deemed to be incorporated
by
51
reference in this prospectus modifies or supersedes such statement. Any
statement so modified or superseded shall not be deemed, except as so modified
or superseded, to constitute a part of this prospectus.
WHERE YOU CAN FIND MORE INFORMATION
We file annual, quarterly and current reports, proxy statements other
information with the SEC. You may read or copy any document we file at the
public reference room maintained by the SEC at 450 Fifth Street, N.W.,
Washington, D.C. 20549. Copies of this information may also be obtained by mail
from the SEC's Public Reference Branch at 450 Fifth Street, N.W., Washington,
D.C. 20549. In addition, our filings with the SEC are also available to the
public on the SEC's internet Web site at http://www.sec.gov. Our Class A common
stock is listed on the New York Stock Exchange, and our reports, proxy
statements and other information concerning us may also be read and copied at
the offices of the NYSE.
We have filed with the SEC a registration statement on Form S-2 under the
Securities Act of 1933 with respect to this rights offering. This prospectus
does not contain all of the information set forth in the registration statement
and its exhibits. Statements made by us in this prospectus as to the contents
of any contract, agreement or other document referred to in this prospectus are
not necessarily complete. For a more complete description of these contracts,
agreements or other documents, you should carefully read the exhibits to the
registration statement and the documents that we reference under the caption
"Incorporation of Certain Documents by Reference."
The registration statement, together with its exhibits and schedules,
which we filed with the SEC, may also be reviewed and copied at the public
reference facilities of the SEC located at the addresses set forth above.
Please call the SEC at 1-800-SEC-0330 for further information on its public
reference facilities.
You should rely only on the information contained, or incorporated by
reference in, this prospectus. We have not authorized anyone to provide
information different from that contained in, or incorporated by reference in,
this prospectus. This prospectus is not an offer to sell or a solicitation of
an offer to buy these securities in any state where the offer or sale is not
permitted. This prospectus is not an offer to sell or a solicitation of an
offer to buy these securities in any circumstance under which the offer or
solicitation is not permitted. The information contained in this prospectus is
correct only as of the date of this prospectus, regardless of the time of the
delivery of this prospectus or any sale of these securities.
52
================================================================================
3,717,391 SHARES
REVLON, INC.
CLASS A COMMON STOCK
---------------------
PROSPECTUS
---------------------
, 2003
================================================================================
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
ITEM 14. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION
Securities and Exchange Commission Registration Fee .......... $ 828
Printing Expenses ............................................ 75,000
Accounting Fees and Expenses ................................. 100,000
Legal Fees and Expenses ...................................... 842,000
Miscellaneous (including financial advisor expenses) ......... 1,608,000
----------
Total ..................................................... $2,625,828
==========
All amounts shown are estimates, except the Securities and Exchange Commission
registration fee.
ITEM 15. INDEMNIFICATION OF DIRECTORS AND OFFICERS
Section 102(b)(7) of the General Corporation Law of the State of Delaware
allows a corporation to eliminate or limit the personal liability of directors
to a corporation or its stockholders for monetary damages for a breach of
fiduciary duty as a director, except where the director breached his duty of
loyalty, failed to act in good faith, engaged in intentional misconduct or
knowingly violated a law, authorized the payment of a dividend or approved a
stock repurchase or redemption in violation of Delaware corporate law or
obtained an improper personal benefit.
Section 145 of the General Corporation Law of the State of Delaware
empowers a Delaware corporation to indemnify any person who was or is a party
or is threatened to be made a party to any threatened, pending or completed
action, suit or proceeding, whether civil, criminal, administrative or
investigative (other than an action by or in the right of such corporation) by
reason of the fact that such person is or was a director, officer, employee or
agent of such corporation, or is or was serving at the request of such
corporation as a director, officer, employee or agent of another corporation,
partnership, joint venture, trust or other enterprise. The indemnity may
include expenses (including attorneys' fees), judgments, fines and amounts paid
in settlement actually and reasonably incurred by such person in connection
with such action, suit or proceeding, provided that such person acted in good
faith and in a manner such person reasonably believed to be in or not opposed
to the best interests of the corporation and, with respect to any criminal
action or proceeding, had no reasonable cause to believe such person's conduct
was unlawful. A Delaware corporation may indemnify directors, officers,
employees and other agents of such corporation in an action by or in the right
of a corporation under the same conditions against expenses (including
attorneys' fees) actually and reasonably incurred by the person in connection
with the defense and settlement of such action or suit, except that no
indemnification is permitted without judicial approval if the person to be
indemnified has been adjudged to be liable to the corporation. Where a present
or former director or officer of the corporation is successful on the merits or
otherwise in the defense of any action, suit or proceeding referred to above or
in defense of any claim, issue or matter therein, the corporation must
indemnify such person against the expenses (including attorneys' fees) which he
or she actually and reasonably incurred in connection therewith.
Article X of the By-laws of Revlon, Inc. (the "Company") provides for
indemnification of the officers and directors of the Company to the fullest
extent permitted by applicable law.
Section 8 of Article X of the By-laws provides that the Company may
purchase and maintain insurance on behalf of its directors and officers. The
indemnification and advancement of expenses shall, unless otherwise provided
when authorized or ratified, continue as to a person who has ceased to be a
director or officer and shall inure to the benefit of the heirs, executors and
administrators of such a person.
Section 11 of Article X of the By-laws provides that except for
proceedings to enforce rights to indemnification, the Company shall not be
obligated to indemnify any director or officer in connection
II-1
with a proceeding (or part thereof) initiated by such person unless such
proceeding (or part thereof) was authorized or consented to by the Board of
Directors of the Company.
Article Fifth (4) of the Company's Amended and Restated Certificate of
Incorporation provides that no director shall be personally liable to the
Company or any of its stockholders for monetary damages for breach of fiduciary
duty as a director, except for liability (i) for any breach of the director's
duty of loyalty to the Company or its stockholders, (ii) for acts or omissions
not in good faith or that involve intentional misconduct or a knowing violation
of law, (iii) pursuant to Section 174 of the General Corporation Law of the
State of Delaware or (iv) for any transaction from which the director derived
an improper personal benefit. Any repeal or modification of this Article by the
stockholders of the Company shall not adversely affect any right or protection
of a director of the Company existing at the time of such repeal or
modification with respect to acts or omissions occurring prior to such repeal
or modification.
ITEM 16. EXHIBITS
The following is a list of all exhibits filed as part of this registration
statement on Form S-2, including those incorporated in this registration
statement by reference.
LOCATION OR INCORPORATION
EXHIBIT NO. DESCRIPTION BY REFERENCE TO
------------- ------------------------------------------ ------------------------------------------
2. PLAN OF ACQUISITION ETC.
2.1 Investment Agreement, dated as of Incorporated by reference to Exhibit 2.1
February 5, 2003, among Revlon, Inc., to the Current Report on Form 8-K of
Revlon Consumer Products Corporation Revlon Consumer Products Corporation
and MacAndrews & Forbes Holdings Inc. ("Products Corporation"), filed with the
Commission on February 5, 2003 (the
"Products Corporation February 2003
Form 8-K")
4. INSTRUMENTS DEFINING THE
RIGHTS OF SECURITY HOLDERS,
INCLUDING INDENTURES.
4.1 Specimen Class A Common Stock Previously filed
Certificate
4.2 Form of Subscription Rights Certificate Previously filed
5. OPINION RE LEGALITY.
5.1 Opinion of Robert K. Kretzman, Esq. Previously filed
8. OPINION RE: TAX MATTERS.
8.1 Opinion of Skadden, Arps, Slate, Previously filed
Meagher & Flom, LLP
10. MATERIAL CONTRACTS.
10.1 Asset Transfer Agreement, dated as of Incorporated by reference to Exhibit 10.1
June 24, 1992, among Revlon Holdings to Amendment No. 1 to the Revlon, Inc.
LLC, National Health Care Group, Inc., Registration Statement on Form S-1 filed
Charles of the Ritz Group Ltd., Products with the Commission on June 29, 1992,
Corporation and Revlon, Inc. File No. 33-47100
II-2
LOCATION OR INCORPORATION
EXHIBIT NO. DESCRIPTION BY REFERENCE TO
------------- ------------------------------------------ -------------------------------------------
10.2 Tax Sharing Agreement, entered into as Incorporated by reference to Exhibit 10.2
of June 24, 1992, among Mafco Holdings to the Annual Report on Form 10-K of
Inc., Revlon, Inc., Products Corporation Products Corporation for the year ended
and certain subsidiaries of Products December 31, 2001, filed with the
Corporation as amended and restated as Commission on February 25, 2002 (the
of January 1, 2001. "Products Corporation 2001 Form 10-K")
10.3 Employment Agreement, dated as of Incorporated by reference to Exhibit
February 17, 2002, between Products 10.17 to the Quarterly Report on Form
Corporation and Jack L. Stahl. 10-Q of Revlon, Inc. for the quarterly
period ended March 31, 2002, filed with
the Commission on May 15, 2002
10.4 Revlon, Inc. 2002 Supplemental Stock Incorporated by reference to Exhibit 4.1
Plan. to the Registration Statement on Form
S-8 of Revlon, Inc. filed with the
Commission on June 24, 2002, File No.
333-91040
10.5 Employment Agreement, amended and Incorporated by reference to Exhibit
restated as of May 9, 2000, between 10.22 to the Quarterly Report on Form
Products Corporation and Douglas H. 10-Q of Revlon, Inc. for the quarterly
Greeff (the "Greeff Employment period ended June 30, 2000, filed with the
Agreement"). Commission on August 14, 2000
10.6 Amendment dated June 18, 2001 to the Incorporated by reference to Exhibit 10.6
Greeff Employment Agreement. to the Products Corporation 2001 Form
10-K
10.7 Employment Agreement, effective as of Incorporated by reference to Exhibit 10.7
August 1, 2001, between Products to the Products Corporation 2001 Form
Corporation and Paul E. Shapiro. 10-K
10.8 Revlon Executive Bonus Plan (Amended Incorporated by reference to Exhibit 10.8
and Restated as of September 1, 2002). to the Annual Report on Form 10-K of
Revlon, Inc. for the year ended
December 31, 2002, filed with the
Commission on March 21, 2003 (the
"Revlon 2002 Form 10-K")
10.9 Amended and Restated Revlon Pension Incorporated by reference to Exhibit
Equalization Plan, amended and restated 10.15 to the Annual Report on Form
as of December 14, 1998. 10-K of Revlon, Inc. for year ended
December 31, 1998, filed with the
Commission on March 3, 1999
II-3
LOCATION OR INCORPORATION
EXHIBIT NO. DESCRIPTION BY REFERENCE TO
------------- ----------------------------------------- -----------------------------------------
10.10 Executive Supplemental Medical Expense Incorporated by reference to Exhibit
Plan Summary dated July 2000. 10.10 to the Revlon 2002 Form 10-K
10.11 Benefit Plans Assumption Agreement, Incorporated by reference to Exhibit
dated as of July 1, 1992, by and among 10.25 to the Annual Report on Form
Revlon Holdings LLC, Revlon, Inc. and 10-K of Products Corporation for the
Products Corporation. year ended December 31, 1992, filed with
the Commission on March 12, 1993
10.12 Revlon Amended and Restated Incorporated by reference to Exhibit
Executive Deferred Compensation Plan 10.27 to the Quarterly Report on Form
dated as of August 6, 1999. 10-Q of Revlon, Inc. for the quarterly
period ended September 30, 1999 filed
with the Commission on November 15,
1999
10.13 Revlon Executive Severance Policy as Incorporated by reference to Exhibit
amended July 1, 2002. 10.13 to the Revlon 2002 Form 10-K
10.14 Revlon, Inc. Fourth Amended and Incorporated by reference to Exhibit 4.1
Restated 1996 Stock Plan. to the Registration Statement on Form
S-8 of Revlon, Inc. filed with the
Commission on June 24, 2002, File No.
333-91038
10.15 Purchase Agreement, dated as of Incorporated by reference to Exhibit
February 18, 2000, by and among Revlon, 10.19 to the Annual Report on Form
Inc., Products Corporation, REMEA 2 10-K of Revlon, Inc. for the year ended
B.V., Revlon Europe, Middle East and December 31, 1999, filed with the
Africa, Ltd., Revlon International Commission on March 30, 2000
Corporation, Europeenne de Produits de
Beaute S.A., Deutsche Revlon GmbH &
Co. K.G., Revlon Canada, Inc., Revlon
de Argentina, S.A.I.C., Revlon South
Africa (Proprietary) Limited, Revlon
(Suisse) S.A., Revlon Overseas
Corporation C.A., CEIL Comercial,
Exportadora, Industrial Ltda., Revlon
Manufacturing Ltd., Revlon Belgium
N.V., Revlon (Chile) S.A., Revlon (Hong
Kong) Limited, Revlon, S.A., Revlon
Nederland B.V., Revlon New Zealand
Limited, European Beauty Products
S.p.A. and Beauty Care Professional
Products Luxembourg, S.a.r.l.
II-4
LOCATION OR INCORPORATION
EXHIBIT NO. DESCRIPTION BY REFERENCE TO
------------- ----------------------------------------- ---------------------------------------
10.16 Purchase and Sale Agreement dated as of Incorporated by reference to Exhibit
July 31, 2001 by and between Revlon 10.16 to the Products Corporation 2001
Holdings LLC and Revlon, Inc. relating Form 10-K
to the Charles of the Ritz business.
10.17 Senior Unsecured Multiple-Draw Term Incorporated by reference to Exhibit
Loan dated as of February 5, 2003, 10.17 to the Products Corporation
between MacAndrews & Forbes February 2003 Form 8-K
Holdings Inc. and Products Corporation.
10.18 Senior Unsecured Supplemental Line of Incorporated by reference to Exhibit
Credit Agreement, dated as of February 10.18 to the Products Corporation
5, 2003, between MacAndrews & Forbes February 2003 Form 8-K
Holdings Inc. and Products Corporation.
23. CONSENTS.
23.1 Consent of Robert K. Kretzman, Esq. Included in Exhibit 5.1
23.2 Consent of KPMG LLP, Independent Included herein
Auditors
23.3 Consent of Skadden, Arps, Slate, Included in Exhibit 8.1
Meagher & Flom LLP
24. POWERS OF ATTORNEY.
24.1 Power of Attorney executed by Ronald Previously filed
O. Perelman
24.2 Power of Attorney executed by Jack L. Previously filed
Stahl
24.3 Power of Attorney executed by Howard Previously filed
Gittis
24.4 Power of Attorney executed by Douglas Previously filed
H. Greeff
24.5 Power of Attorney executed by Donald Previously filed
G. Drapkin
24.6 Power of Attorney executed by Meyer Previously filed
Feldberg
24.7 Power of Attorney executed by Vernon Previously filed
E. Jordan, Jr.
24.8 Power of Attorney executed by Edward Previously filed
J. Landau
24.9 Power of Attorney executed by Linda Previously filed
Gosden Robinson
24.10 Power of Attorney executed by Terry Previously filed
Semel
II-5
LOCATION OR INCORPORATION
EXHIBIT NO. DESCRIPTION BY REFERENCE TO
------------- ------------------------------------------- --------------------------
24.11 Power of Attorney executed by Martha Previously filed
Stewart
99. ADDITIONAL EXHIBITS.
99.1 Form of Instructions for Use of Revlon, Previously filed
Inc. Subscription Rights Certificates
99.2 Form of Notice of Guaranteed Delivery Previously filed
for Subscription Rights
99.3 Form of Letter to Stockholders Who Are Previously filed
Record Holders
99.4 Form of Letter to Stockholders Who Are Previously filed
Beneficial Holders
99.5 Form of Letter to Clients of Stockholders Previously filed
Who Are Beneficial Holders
99.6 Form of Nominee Holder Certification Previously filed
Form
99.7 Form of Beneficial Owner Election Form Previously filed
99.8 Form of 401(k) Plan Participant Election Previously filed
Form
99.9 Form of Letter to Participants in the Previously filed
Revlon 401(k) Plan
99.10 Form of Notice to Participants in the Previously filed
Revlon 401(k) Plan
ITEM 17. UNDERTAKINGS
The undersigned registrant hereby undertakes:
(1) To file, during any period in which offers or sales are being made,
a post-effective amendment to this registration statement:
(i) To include any prospectus required by section 10(a)(3) of the
Securities Act of 1933;
(ii) To reflect in the prospectus any facts or events arising after
the effective date of the registration statement (or the most recent
post-effective amendment thereof) which, individually or in the
aggregate, represent a fundamental change in the information in the
registration statement. Notwithstanding the foregoing, any increase or
decrease in volume of securities offered (if the total dollar value of
securities offered would not exceed that which was registered) and any
deviation from the low or high end of the estimated maximum offering
range may be reflected in the form of prospectus filed with the
Commission pursuant to Rule 424(b) if, in the aggregate, the changes in
volume and price represent no more than 20 percent change in the
maximum aggregate offering price set forth in the "Calculation of
Registration Fee" table in the effective registration statement; and
(iii) To include any material information with respect to the plan of
distribution not previously disclosed in the registration statement or
any material change to such information in the registration statement.
(2) That, for the purpose of determining any liability under the
Securities Act of 1933, each such post-effective amendment shall be deemed
to be a new registration statement relating to the securities offered
therein, and the offering of such securities at that time shall be deemed
to be the initial bona fide offering thereof.
II-6
(3) To remove from registration by means of a post-effective amendment
any of the securities being registered which remain unsold at the
termination of the offering.
Insofar as indemnification for liabilities arising under the Securities
Act of 1933 may be permitted to directors, officers and controlling persons of
the registrant pursuant to the foregoing provisions, or otherwise, the
registrant has been advised that in the opinion of the SEC such indemnification
is against public policy as expressed in the Securities Act of 1933 and is,
therefore, unenforceable. In the event that a claim for indemnification against
such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer or controlling person of the registrant in the
successful defense of any action, suit or proceeding) is asserted by such
director, officer or controlling person in connection with the securities being
registered, the registrant will, unless in the opinion of its counsel that
matter has been settled by controlling precedent, submit to a court of
appropriate jurisdiction the question whether such indemnification by it is
against public policy as expressed in the Securities Act of 1933 and will be
governed by the final adjudication of such issue.
The undersigned registrant hereby undertakes that:
(1) For purposes of determining any liability under the Securities Act
of 1933, the information omitted from the form of prospectus filed as part
of this registration statement in reliance upon Rule 430A and contained in
a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or
(4) or 497(h) under the Securities Act shall be deemed to be part of this
registration statement as of the time it was declared effective; and
(2) For the purpose of determining any liability under the Securities
Act of 1933, each post-effective amendment that contains a form of
prospectus shall be deemed to be a new registration statement relating to
the securities offered in any such amendment, and the offering of such
securities at that time shall be deemed to be the initial bona fide
offering of such securities.
II-7
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant
certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form S-2 and has duly caused this Amendment No. 3 to
the Registration Statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in the City of New York, State of New York on the
2nd day of May, 2003.
REVLON, INC.
By: /s/ Robert K. Kretzman
----------------------
Name: Robert K. Kretzman
Title: Senior Vice President
Pursuant to the requirements of the Securities Act of 1933, this Amendment
No. 3 to the Registration Statement has been signed by the following persons in
the capacities and on the dates indicated:
SIGNATURE TITLE DATE
* Chairman of the Board and May 2, 2003
------------------------- Director
Ronald O. Perelman
/s/ Jack L. Stahl President, Chief Executive Officer May 2, 2003
------------------------- and Director (Principal Executive
Jack L. Stahl Officer)
/s/ Douglas H. Greeff Executive Vice President and May 2, 2003
------------------------- Chief Financial Officer (Principal
Douglas H. Greeff Financial Officer)
* Director May 2, 2003
-------------------------
Howard Gittis
* Director May 2, 2003
-------------------------
Donald G. Drapkin
* Director May 2, 2003
-------------------------
Meyer Feldberg
* Director May 2, 2003
-------------------------
Vernon E. Jordan, Jr.
* Director May 2, 2003
-------------------------
Edward J. Landau
* Director May 2, 2003
-------------------------
Linda Godsen Robinson
* Director May 2, 2003
-------------------------
Terry Semel
* Director May 2, 2003
-------------------------
Martha Stewart
/s/ Laurence Winoker Senior Vice President, Corporate May 2, 2003
------------------------- Controller and Treasurer (Principal
Laurence Winoker Accounting Officer)
* Robert K. Kretzman, by signing his name hereto, does hereby sign this
Amendment No. 3 to the Registration Statement on behalf of the directors
of the registrant above whose typed names asterisks appear, pursuant to
powers of attorney duly executed by such directors and filed with the
Securities and Exchange Commission.
By: /s/ Robert Kretzman
-------------------------
Name: Robert K. Kretzman
Title: Attorney-in-fact
II-8
EXHIBIT INDEX
LOCATION OR INCORPORATION
EXHIBIT NO. DESCRIPTION BY REFERENCE TO
------------- ------------------------------------------ ------------------------------------------
2. PLAN OF ACQUISITION ETC.
2.1 Investment Agreement, dated as of Incorporated by reference to Exhibit 2.1
February 5, 2003, among Revlon, Inc., to the Current Report on Form 8-K of
Revlon Consumer Products Corporation Revlon Consumer Products Corporation
and MacAndrews & Forbes Holdings Inc. ("Products Corporation"), filed with the
Commission on February 5, 2003 (the
"Products Corporation February 2003
Form 8-K"
4. INSTRUMENTS DEFINING THE
RIGHTS OF SECURITY HOLDERS,
INCLUDING INDENTURES.
4.1 Specimen Class A Common Stock Previously filed
Certificate
4.2 Form of Subscription Rights Certificate Previously Filed
5. OPINION RE LEGALITY.
5.1 Opinion of Robert K. Kretzman, Esq. Previously filed
8. OPINION RE TAX MATTERS.
8.1 Opinion of Skadden, Arps, Slate, Previously filed
Meagher & Flom, LLP
10. MATERIAL CONTRACTS.
10.1 Asset Transfer Agreement, dated as of Incorporated by reference to Exhibit 10.1
June 24, 1992, among Revlon Holdings to Amendment No. 1 to the Revlon, Inc.
LLC, National Health Care Group, Inc., Registration Statement on Form S-1 filed
Charles of the Ritz Group Ltd., Products with the Commission on June 29, 1992,
Corporation and Revlon, Inc. File No. 33-47100
10.2 Tax Sharing Agreement, entered into as Incorporated by reference to Exhibit 10.2
of June 24, 1992, among Mafco Holdings to the Annual Report on Form 10-K of
Inc., Revlon, Inc., Products Corporation Products Corporation for the year ended
and certain subsidiaries of Products December 31, 2001, filed with the
Corporation as amended and restated as Commission on February 25, 2002 (the
of January 1, 2001. "Products Corporation 2001 Form 10-K")
10.3 Employment Agreement, dated as of Incorporated by reference to Exhibit
February 17, 2002, between Products 10.17 to the Quarterly Report on Form
Corporation and Jack L. Stahl. 10-Q of Revlon, Inc. for the quarterly
period ended March 31, 2002, filed with
the Commission on May 15, 2002
10.4 Revlon, Inc. 2002 Supplemental Stock Incorporated by reference to Exhibit 4.1
Plan. to the Registration Statement on
Form S-8 of Revlon, Inc. filed with the
Commission on June 24, 2002, File
No. 333-91040
II-9
LOCATION OR INCORPORATION
EXHIBIT NO. DESCRIPTION BY REFERENCE TO
------------- ----------------------------------------- ------------------------------------------
10.5 Employment Agreement, amended and Incorporated by reference to
restated as of May 9, 2000, between Exhibit 10.22 to the Quarterly Report on
Products Corporation and Douglas H. Form 10-Q of Revlon, Inc. for the
Greeff (the "Greeff Employment quarterly period ended June 30, 2000,
Agreement"). filed with the Commission on August 14,
2000
10.6 Amendment dated June 18, 2001 to the Incorporated by reference to Exhibit 10.6
Greeff Employment Agreement. to the Products Corporation 2001
Form 10-K
10.7 Employment Agreement, effective as of Incorporated by reference to Exhibit 10.7
August 1, 2001, between Products to the Products Corporation 2001
Corporation and Paul E. Shapiro. Form 10-K
10.8 Revlon Executive Bonus Plan (Amended Incorporated by reference to Exhibit 10.8
and Restated as of September 1, 2002). to the Annual Report on Form 10-K of
Revlon, Inc. for the year ended
December 31, 2002, filed with the
Commission on March 21, 2003 (the
"Revlon 2002 Form 10-K")
10.9 Amended and Restated Revlon Pension Incorporated by reference to
Equalization Plan, amended and restated Exhibit 10.15 to the Annual Report on
as of December 14, 1998. Form 10-K of Revlon, Inc. for year
ended December 31, 1998, filed with the
Commission on March 3, 1999
10.10 Executive Supplemental Medical Expense Incorporated by reference to
Plan Summary dated July 2000. Exhibit 10.10 to the Revlon 2002
Form 10-K
10.11 Benefit Plans Assumption Agreement, Incorporated by reference to
dated as of July 1, 1992, by and among Exhibit 10.25 to the Annual Report on
Revlon Holdings LLC, Revlon, Inc. and Form 10-K of Products Corporation for
Products Corporation. the year ended December 31, 1992, filed
with the Commission on March 12, 1993
10.12 Revlon Amended and Restated Incorporated by reference to
Executive Deferred Compensation Plan Exhibit 10.27 to the Quarterly Report on
dated as of August 6, 1999. Form 10-Q of Revlon, Inc. for the
quarterly period ended September 30,
1999 filed with the Commission on
November 15, 1999
10.13 Revlon Executive Severance Policy as Incorporated by reference to
amended July 1, 2002. Exhibit 10.13 to the Revlon 2002
Form 10-K
10.14 Revlon, Inc. Fourth Amended and Incorporated by reference to Exhibit 4.1
Restated 1996 Stock Plan. to the Registration Statement on
Form S-8 of Revlon, Inc. filed with the
Commission on June 24, 2002, File
No. 333-91038
II-10
LOCATION OR INCORPORATION
EXHIBIT NO. DESCRIPTION BY REFERENCE TO
------------- ----------------------------------------- ----------------------------------------
10.15 Purchase Agreement, dated as of Incorporated by reference to
February 18, 2000, by and among Revlon, Exhibit 10.19 to the Annual Report on
Inc., Products Corporation, REMEA 2 Form 10-K of Revlon, Inc. for the year
B.V., Revlon Europe, Middle East and ended December 31, 1999, filed with the
Africa, Ltd., Revlon International Commission on March 30, 2000
Corporation, Europeenne de Produits de
Beaute S.A., Deutsche Revlon GmbH &
Co. K.G., Revlon Canada, Inc., Revlon
de Argentina, S.A.I.C., Revlon South
Africa (Proprietary) Limited, Revlon
(Suisse) S.A., Revlon Overseas
Corporation C.A., CEIL Comercial,
Exportadora, Industrial Ltda., Revlon
Manufacturing Ltd., Revlon Belgium
N.V., Revlon (Chile) S.A., Revlon (Hong
Kong) Limited, Revlon, S.A., Revlon
Nederland B.V., Revlon New Zealand
Limited, European Beauty Products
S.p.A. and Beauty Care Professional
Products Luxembourg, S.a.r.l.
10.16 Purchase and Sale Agreement dated as of Incorporated by reference to Exhibit
July 31, 2001 by and between Revlon 10.16 to the Products Corporation 2001
Holdings LLC and Revlon, Inc. relating Form 10-K
to the Charles of the Ritz business.
10.17 Senior Unsecured Multiple-Draw Term Incorporated by reference to
Loan dated as of February 5, 2003, Exhibit 10.17 to the Products
between MacAndrews & Forbes Corporation February 2003 Form 8-K
Holdings Inc. and Products Corporation.
10.18 Senior Unsecured Supplemental Line of Incorporated by reference to
Credit Agreement, dated as of Exhibit 10.18 to the Products
February 5, 2003, between MacAndrews Corporation February 2003 Form 8-K
& Forbes Holdings Inc. and Products
Corporation.
23. CONSENTS.
23.1 Consent of Robert K. Kretzman, Esq. Included in Exhibit 5.1
23.2 Consent of KPMG LLP, Independent Included herein
Auditors
23.3 Consent of Skadden, Arps, Slate, Included in Exhibit 8.1
Meagher & Flom LLP
24. POWERS OF ATTORNEY.
24.1 Power of Attorney executed by Ronald Previously filed
O. Perelman
24.2 Power of Attorney executed by Jack L. Previously filed
Stahl
II-11
LOCATION OR INCORPORATION
EXHIBIT NO. DESCRIPTION BY REFERENCE TO
------------- ------------------------------------------- --------------------------
24.3 Power of Attorney executed by Howard Previously filed
Gittis
24.4 Power of Attorney executed by Douglas Previously filed
H. Greeff
24.5 Power of Attorney executed by Donald Previously filed
G. Drapkin
24.6 Power of Attorney executed by Meyer Previously filed
Feldberg
24.7 Power of Attorney executed by Vernon Previously filed
E. Jordan, Jr.
24.8 Power of Attorney executed by Edward Previously filed
J. Landau
24.9 Power of Attorney executed by Linda Previously filed
Gosden Robinson
24.10 Power of Attorney executed by Terry Previously filed
Semel
24.11 Power of Attorney executed by Martha Previously filed
Stewart
99. ADDITIONAL EXHIBITS.
99.1 Form of Instructions for Use of Revlon, Previously filed
Inc. Subscription Rights Certificates
99.2 Form of Notice of Guaranteed Delivery Previously filed
for Subscription Rights
99.3 Form of Letter to Stockholders Who Are Previously filed
Record Holders
99.4 Form of Letter to Stockholders Who Are Previously filed
Beneficial Holders
99.5 Form of Letter to Clients of Stockholders Previously filed
Who Are Beneficial Holders
99.6 Form of Nominee Holder Certification Previously filed
Form
99.7 Form of Beneficial Owner Election Form Previously filed
99.8 Form of 401(k) Plan Participant Election Previously filed
Form
99.9 Form of Letter to Participants in the Previously filed
Revlon 401(k) Plan
99.10 Form of Notice to Participants in the Previously filed
Revlon 401(k) Plan
II-12